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Abstract 
Heart failure is one of the leading causes of death worldwide, with rising impact with the 
increasing ageing population. This is in sharp contrast with the limited and non-ideal 
therapies available. Approximately 50% of deaths from heart failure are sudden and 
unexpected, and presumably the consequence of lethal ventricular arrhythmias. Despite 
significant reduction of mortality from sudden cardiac death achieved by ICDs and drugs 
such as beta-blockers, there remains a large room for improving the survivability of heart 
failure patients by advancing our understanding of arrhythmogenesis from molecular level to 
multi-cellular tissue level. Another important aspect of heart failure is abnormal excitation-
contraction (EC) coupling and calcium handling, functional changes of which exert great 
impact on both arrhythmia vulnerability and pump failure. Advancing the understanding the 
remodeling of EC coupling and calcium handling might provide potential molecular and 
anatomical targets for clinical intervention.  
    In this dissertation, I first developed two optical imaging systems (both hardware and 
software) for quantifying the conduction, repolarization and excitation-contraction coupling. 
The first one is the panoramic imaging system for mapping the entire ventricular epicardium 
of a rabbit heart. The second one is the dual imaging system for simultaneous measurement 
of action potential and calcium transient.  
    Using the systems I developed, I conducted two rabbit studies to investigate the role 
electrical instability and structural heterogeneity in the induction and maintenance of 
arrhythmias. We first identified the importance of both dynamic instability and effective 
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tissue size in the spontaneous termination of arrhythmia in the normal rabbit heart. We then 
identified novel mechanism of how healed myocardial infarction promotes the induction of 
ventricular arrhythmia.  
    Finally, guided by the knowledge from the animal studies, I studied the failing human 
heart with the aim to advance our understanding of cardiac electrophysiology in human heart 
failure. We first demonstrated the transmural heterogeneity of EC coupling in nonfailing 
heart and identified potential mechanisms of electrical and mechanical dysfunction by 
quantifying the remodeling of EC coupling. We then studied the remodeling of conduction 
and repolarization with the aim to determine of the role of dispersion of repolarization and 
electrical instability in the induction of arrhythmia in human heart failure.  
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1. Introduction 
1.1 Background and Motivation 
Heart failure is one of the leading causes of death worldwide. It claims over 250,000 lives 
annually in the United States alone (2). Despite great basic and clinical research efforts and 
advances, the available therapies for heart failure remain limited and not ideal. This is largely 
due to the complex nature of the disease and difficulties in translating the knowledge from 
animal studies to patients with heart failure. It is therefore important to continue advancing 
our understanding of the underlying mechanisms leading to electrical and mechanical 
dysfunction in both animal models and heart failure patients for the development of device-
based and molecular therapies.  
    There are two important intertwined areas of research in heart failure. One area is the 
study of ventricular arrhythmia, which is responsible for the sudden cardiac death that 
accounts for approximately 50% of deaths from heart failure. Despite the significant 
reduction of mortality achieved by ICDs and non-antiarrhythmic drugs such as beta-blockers, 
it remains a big challenge to reverse the prognosis and cure the disease. A better 
understanding of the arrhythmic mechanism will help early diagnosis, target identification of 
intervention and hopefully lead to therapies that completely eliminate the trigger and 
substrate of the lethal ventricular arrhythmia.  
    Another important aspect of heart failure is the impaired excitation-contraction (EC) 
coupling and calcium handling, abnormal remodeling of which enhances both arrhythmia 
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vulnerability and pump failure. Molecular therapies targeting the key EC coupling proteins 
are under intensive basic and clinical investigation and might become an attractive 
therapeutic alternative in the near future. On the other hand, clinical translation is limited by 
our incomplete understanding of the molecular and functional remodeling of EC coupling in 
heart failure.  
    Basic studies of heart failure using animal models allow detailed and controlled 
mechanistic investigations of cardiac electrical and mechanical dysfunction. However, direct 
extrapolation of animal model results to patients are complicated not only by the great 
variations in normal cardiac electrophysiology in animal species, but also by the array of 
heart failure models used (including ischemic, pacing-induced, toxin-induced, genetic 
modification, pressure overload, and volume overload models). Therefore, any hypotheses 
derived from the animal models should be tested directly in human heart.  
1.2  Scope and Outline of the Dissertation 
In this dissertation, we aimed to first develop advanced optical imaging systems for the 
functional studies of cardiac electrophysiology, then to explore the role of conduction, 
repolarization, and EC coupling in the rabbits, and finally to test the obtained hypothesis 
directly in the humans with and without heart failure.   
    Chapter 2 will describe the development of panoramic optical imaging system. The dual 
optical imaging system will be briefly described in the Appendix B. Chapter 3 will present my 
first rabbit study exploring the mechanisms of arrhythmia maintenance and self-termination. 
Chapter 4 describes my second rabbit study exploring the arrhythmogenesis in the presence 
of healed myocardial infarction. Chapter 5 is a description of a human study to test the 
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hypothesis obtained from my animal studies in human heart failure. Before further 
experimental data are presented, Chapter 6 provides an overview of the remodeling of 
calcium handling in human heart failure. Afterwards, a study of EC coupling remodeling in 
failing human heart is presented in Chapter 7. Finally, summary and future direction are 
presented in Chapter 8.  
  
4 
 
2. Quantitative Panoramic Imaging of Epicardial 
Electrical Activity 
2.1 Abstract 
Fluorescent imaging with voltage- and/or calcium-sensitive dyes has revolutionized cardiac 
physiology research. Here we present improved panoramic imaging for optically mapping 
electrical activity from the entire epicardium of the Langendorff-perfused rabbit heart. 
Combined with reconstruction of the 3D heart surface, the functional data can be 
conveniently visualized on the realistic heart geometry. Methods to quantify the panoramic 
data set are introduced by first describing a simple approach to mesh the heart in regular grid 
form. The regular grid mesh provides substrate for easy translation of previously available 
non-linear dynamics methods for 2D array data. It also simplifies the unwrapping of curved 
three-dimensional surface to 2D surface for global epicardial visualization of the functional 
data. The translated quantification methods include activation maps (isochrones), phase 
maps, phase singularity and electric stimulus induced virtual electrode polarization (VEP) 
maps. We also adapt a method to calculate the conduction velocities on the global epicardial 
surface by taking the curvature of the heart surface into account.  
2.2  Introduction 
Transmembrane potential on the epicardial surface of the heart can be recorded optically 
(178). To maximize the field of view, panoramic optical imaging was introduced by Lin et al. 
(151) to map the entire ventricular epicardium from three different angles around the heart. 
Later, more efforts were devoted to this novel imaging methodology. Bray et al. (28) 
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proposed to reconstruct the heart geometry and texture map the optical signal onto the 
geometric surface for better visualization. Kay et al. (124) implemented panoramic optical 
mapping on swine hearts, and Rogers et al. (223, 224) applied this technology in research of 
ventricular fibrillation. More recently, our group (213) developed a panoramic imaging 
system using three photo-diode arrays (PDAs, Hamamatsu) with high temporal resolution 
for research on mechanisms of cardiac defibrillation. A sketch of this system is shown in 
Appendix A.  
    While panoramic imaging systems are being improved, the data analysis methods designed 
for panoramic data sets are still limited. One reason is that the available analysis tools do not 
easily lend themselves to the unstructured triangular mesh of the heart surface geometry. In 
this study, we employed a way to mesh the heart surface for translation of some common 
2D analysis methods. Additionally, conduction velocity vector fields were estimated from the 
panoramic data set for the first time.   
2.3 Methods 
2.3.1 Optical Mapping Experiments 
The panoramic optical mapping system and Langendorff-perfused rabbit heart have been 
described previously (213). Briefly, three photo-diode arrays facing the heart were spaced 
120 apart in the perfusion chamber. Light emitting diode arrays were used as excitation light 
source for the voltage-sensitive dye. This system provides high temporal resolution (5000 
frames/s) and sufficient spatial resolution (1.72mm without interpolation). The excitation-
contraction uncoupler blebbistatin (75) was used to suppress motion artifacts during optical 
recording. Thirty-six images of the heart were taken every 10 as the heart was rotated a full 
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360 at the end of the experiments for geometric reconstruction. Optical signals were 
registered with and texture-mapped onto the surface of the reconstructed geometry.  
 
Figure 1. Reconstruction of heart geometry. (A) Pillars used as the building block for the geometry. (B) 
Digital image of the heart and silhouette image. (C) Refinement of the pillars using the silhouette image. First 
the two end points of pillars were projected onto the images. The projections were then connected by a line 
which might intersect with the contour of the heart. The portions outside the contour were cropped off. And the 
corresponding part of the pillar was also cropped off. (D) The final reconstructed geometry of one heart.  
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2.3.2 Geometry Reconstruction and Registration 
The geometry of the rabbit heart was reconstructed through thirty-six digital images of the 
heart using Niem’s method(192). The procedures are illustrated in Fig. 1. A volume cube 
composed of pillar elements (Fig. 1A) was used as the first crude model of the heart for 
further refinement. The individual pillar was then projected consecutively into the digital 
images and tested for intersections with the object silhouettes (Fig. 1C). The part whose 
projection was outside the object silhouettes was carved off. By refining the volume cube 
with all the silhouettes in digital images, the geometry of the heart is reconstructed with 
sufficient details (Fig. 1D).  
 
Figure 2. Registration of the recorded fluorescent signal with the reconstructed geometric surface. The images in 
the first row are digital images of the heart at the image plane of the PDAs. Red dots in second-row images 
are projections of the surface points of reconstructed geometry of the heart. Good registrations were reached 
when the shape of projections match and overlap the heart in the digital images. 
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    The registration of the signal with the geometric surface is accomplished by first 
projecting the reconstructed geometry onto the image plane of every PDA and then 
matching the projection with region of the heart ―seen‖ by every PDA. Before each optical 
mapping study, a frosted glass was placed in the same location of image plane of every PDA 
and a digital image of the frosted glass was acquired. From these images the heart region for 
optical mapping from individual PDA was determined. Good registration is achieved when 
the projection (red dots in Fig. 2) perfectly matches the heart regions in the image plane of 
PDAs.   
2.3.3 Unwrapping Heart Surface into 2D Map 
Taking an approach similar to those used in cartography, the surface of the heart was 
―unwrapped‖ into a 2D flat map. This allows (1) global visualization of the data in a flat 
plane and (145) the direct utilization of well-established 2D analysis methods, such as 
isochronal mapping, estimation of conduction velocity vectors, and phase mapping.  
    The starting point of the unwrapping procedure is the identification of a large number of 
points (Fig. 3A) lying on the surface of the heart geometry; the coordinates of these points 
are obtained from geometric reconstruction described in the previous section. The 
geometrical center of the heart is found by averaging the coordinates of all the heart surface 
points. Then the ―longitude and latitude‖ of each point are calculated by transforming the 
Cartesian coordinates (x, y, z) to spherical coordinates (θ, φ, r), where θ, φ are the 
counterparts of longitude and latitude in the case of earth, and r  is the distance between that 
point and the geometric center of the heart. The magnitude of r is represented by color in 
Fig. 3B. By redrawing every point in the θ - φ plane, we unwrap the heart surface into a two-
dimensional ―map‖. Again, the color of each point in Fig. 3C represents the magnitude of r.  
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Figure 3. Meshing the heart surface. (A) Surface points obtained from geometric 3D reconstruction from 
multiple views. (B) Surface points coded with color which represents the distance to the geometric center of the 
heart. (C) Surface points unwrapped onto the (θ, φ) plane. (D) Linear interpolation of surface points into an 
evenly spaced (θ, φ) grid. (E) Meshed surface wrapped from interpolated grid. (F) Completed meshed surface. 
 
We then define an evenly spaced (θ, φ) grid, and interpolate r on this grid (Fig. 3D). Each 
grid element corresponds to a specific (θ, φ) pair. This procedure creates a 2D-grid 
representation of the heart surface which is compatible with many available data analysis 
tools. By connecting points with the same θ, and also points with the same φ in 3D space, we 
can generate a mesh (Figs. 3E&F) with lines mimicking the longitudes and latitudes in the 
Earth globe.  
    The resultant (θ, φ) plane is the 2D representation of the originally curved and 
topologically closed 3D surface. While it is a distorted representation of the curved heart 
surface, it provides an alternative way to visualize the epicardial activation, especially for 
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global visualization without the necessity of rotating the heart. More importantly, it 
transforms the data structure into grid form so that common 2D analysis methods can be 
easily applied. Furthermore, if correlation between electrical activity and anatomical features 
is essential, we can also texture-map the anatomy onto the (θ, φ) plane.  
2.3.4 Translate Data Analysis Methods 
A variety of techniques to visualize and analyze the data were implemented, including maps 
of transmembrane voltage (V), dV/dt, phase, phase singularities, activation times, 
conduction velocity, and electric stimulus induced VEP. Fluorescent signals were recorded 
from the PDAs. The signals were first normalized and then interpolated before being 
texture-mapped onto the surface.  
    Phase map is a unique tool for arrhythmic activity. It is based on phase plane analysis and 
facilitates visualization of wave fronts and wave breaks. Phase can be obtained using the 
method proposed by Bray et al. (29). Briefly, the phase  , ,t   is obtained by  
 
 
 
' , ,
, , arctan
' , ,
V t
t
H V t
 
  
 

  
 , 
where  ' , ,V t   is the transmembrane voltage processed by the proper orthogonal 
decomposition, and  ' , ,H V t     is the Hilbert transform of  ' , ,V t   and represents a 
signal with a 2  phase lag relative to  ' , ,V t  .  
    Rotors or wave breaks during cardiac fibrillation correspond to the phase singularities in 
the phase map. The calculation of phase singularity was implemented based on the method 
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described by Bray et al. (31). Briefly, the gradient of phase was first calculated along two 
dimensions of the θ - φ grid,  
[ , ] [ 1, ] [ , ];
[ , ] [ , 1] [ , ];
m n m n m n
m n m n m n


  
  
   
   
 
    Topological charge is then calculated using convolution between the gradients and 3×3 
kernel which mimic the line integral of phase gradients along a closed curve surrounding a 
point. That is,  
        where 
0 0 0 0 1 1
1 0 1 , 0 0 0
1 0 1 0 1 1
 
   
       
   
        
. A point is recognized 
as a phase singularity if its topological charge is 2 or 2 .   
    Activation time was obtained using   
max
, ,dV t dt  , from which the isochrones were 
generated.  
    All the methods described in this section can be first implemented in the (θ, φ) plane, and 
then wrapped back onto the 3D heart surface. It should be noted that we cannot directly 
apply this procedure to calculate the conduction velocity because distance is distorted in the 
(θ, φ) plane.  
2.3.5 Conduction Velocity on the 3D Surface 
Conduction velocity is an important parameter in determining the heart’s susceptibility to 
arrhythmia. With the knowledge of the epicardial geometry, we are able to quantify 
conduction velocity on the whole heart surface.  
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    One approach to calculate the conduction velocity in a 2D (x-y) plane has been proposed 
by Bayly et al. (11) Since the heart surface is essentially three dimensional, this method 
cannot be directly applied. We adapted this method and extended its usage in our panoramic 
data set. First, we define the activation time t as a function of θ and φ like 
  2 2,t a b c d e f            , where θ and φ are spherical coordinates and has 
been calculated when we mesh the heart. Coefficients a,b,…,f are obtained by polynomial 
fitting using (t, θ, φ) in the pre-defined time and space windows. ∂t/∂θ and ∂t/∂φ can then be 
calculated. The gradient of t is determined using 
1 1ˆ ˆ ˆ
sin
t t t
t r
r r r
 
  
  
   
  
. Since 
∇ t is zero along the direction normal to the surface, its projection on the direction normal 
to the surface should be equal to zero, that is,   
 0............
1 1ˆ ˆ ˆ ˆ 1
sin
n
t t t
r e
r r r
 
  

   
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where ˆne  is the unit vector normal to the surface, and ˆ  ˆ  rˆ  are unit vectors in 
spherical coordinates. Since we know ∂t/∂θ and ∂t/∂φ, we can get ∂t/∂r by solving equation 
(1).  
    We then define two orthogonal axes, x and y, which are tangent to the surface; and 
calculate ∂t/∂x and ∂t/∂y by 
t r
r x
 
 
and
t r
r y
 
 
.  ∂t/∂x and ∂t/∂y fully represent ∇ t because 
∇ t is tangent to the surface. Finally we can calculate the conduction velocity (CV) using 
2 2 2 2
, ,
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x y x y
ttdx dy
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dt dt t t t t
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x

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
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t
t
y



. 
13 
 
Simulations were performed to test the accuracy of this method on a meshed sphere 
which mimics the geometry of the heart. The mesh density of the sphere is set to be close to 
that of the reconstructed heart surface. A propagating wave is initiated from one surface 
point of the sphere, and radially propagates out on the surface at constant speed (Fig. 4A). 
The propagating wave with square cross sections was generated by the function
    , , , sin rf x y z t sign wt k r  , where r is the surface distance away from the wave 
initiation site. The surface distance is the shortest distance between two points on the 
surface. The exact speed of propagation is / rw k . The performance of this method was 
tested by calculating the deviation of the estimated from the exact propagation speed.  
 
Figure 4. Simulation of pacing in a spherical surface. (A) Activation map in the sphere surface by point 
stimulation at the location noted by an asterisk. The wave propagates radially in a constant speed on the 
surface. (B) Dependence of the error of conduction velocity on the spatial and temporal “windows” of the 
fitting region. Suppose one active point, named as center point, is active at Ta. Other active points, which are 
active at Ti, are included in fitting if their distance from the center point is less than Δr, and |Ti-Ta|< Δt.  
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2.4 Results 
2.4.1 Function Together with Anatomy 
Figure 5 shows the unwrapped anatomy, transmembrane voltage (V), dV/dt, phase map, and 
phase singularity in the (θ, φ) plane. Figure 5A is the anatomy map, which is obtained by first 
texture mapping the digital images of anatomy onto the reconstructed geometric surface and 
then unwrapping it into a flat plane. This unwrapped anatomy provides a unique way to 
correlate the functional data to the anatomy. Figure 5B is a snapshot of transmembrane 
voltage 230ms after initiation of ventricular fibrillation. The value is normalized into -
85~15mV from the recorded fluorescent signal. Figure 5C is a snapshot of normalized 
dV/dt, where the largest values correspond to the wave fronts. Figure 5D is the phase map, 
with phase zero corresponding to the wave front. Figure 5E shows the distribution of phase 
singularities. Blue dots are the rotors of clockwise rotation of wavefront, while red dots are 
the rotors of counterclockwise rotation.  
    While the unwrapped view provides a global sense of wave propagation on the 
epicardium, data visualization on the reconstructed heart geometry provide an undistorted 
image of the electrical activation. It also allows for easy registration with the anatomy in the 
digital images at different angles. Figure 6 includes all the data presentations on the 
reconstructed geometry.  
By mapping the whole ventricle, we are able to globally track the positions of phase 
singularities, which reveal the dynamics of the ventricular arrhythmia. The first image of 
Figure 7 shows the combined image of anatomy and trajectories of phase singularities during 
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a certain time period of self-terminated arrhythmia. The phase singularity starts from point A, 
then travels to points B, C, D, and finally hits the AV boundary and terminates. The  
 
Figure 5. Unwrapped presentations. (A) Unwrapped epicardium obtained from digital photographs of the 
heart. The dashed line represents the septum. (B) Unwrapped epicardial transmembrane voltage (V) during 
ventricular fibrillation. The data is transformed to -85mV to 15mV range from normalized fluorescent 
signal. (C) Unwrapped dV/dt map with value normalized to 0~1. (D) Unwrapped phase map. (E) Phase 
singularities. Blue dots represent clockwise rotation while red dots represent counterclockwise rotation.  
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Figure 6. Wrapped presentations. Specific notations are present in the figure. The time interval of isochrones 
is 2ms. 
 
 
Figure 7. Trajectories of phase singularity (PS). The left-most panel is the trajectories of phase singularities 
on the anatomy. The phase maps corresponding to four phase singularities (A, B, C and D) are also shown. 
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remaining images of Fig. 7 show the corresponding phase map when the phase singularity is 
at individual point A, B, C and D. Overall, the ability of global visualization of phase 
singularities allows the investigation of the nonlinear dynamics of the ventricular arrhythmia 
especially when the phase singularity is meandering. Furthermore, the ability to correlate 
phase singularity with anatomy provides the potentials to investigate the relationship 
between phase singularity and structural heterogeneities. 
 
Figure 8. Shock-induced virtual electrode (VEP) map. (A) Anterior view. (B) Posterior view. 
 
    Shock-induced VEP is an important mechanism for success and failure of defibrillations 
(40, 64, 66). Figure 8 shows the VEP induced by far field shock at approximately 85% of 
APD80. It is already known (64) that shock-induced VEP could generate higher VEP 
gradient at both base and apex than region in between from anterior view (Fig. 8A), thus 
creating condition for reentry. With the panoramic setup, not only is the anterior VEP 
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pattern visible, but also the posterior (Fig. 8B). In Fig. 8B, the posterior view shows higher 
gradient in the base and apex also, similar to what we saw from the anterior. Overall there 
are four phase singularities created, two in the anterior and two in the posterior. This creates 
a condition for quatrefoil reentry. Since reentry is unstable in a young normal rabbit heart, 
the arrhythmia self-terminates after one rotation.  
2.4.2 Conduction Velocity in Simulations and Epicardial Pacing 
In the simulation, radially propagating waves were constructed on a meshed sphere to mimic 
epicardial pacing in the heart surface. We optimized the velocity estimation method and 
tested its validity while changing the size of the spatiotemporal region (the ―time window‖ 
and ―space window‖) used for polynomial fitting.  
    We found that estimates of conduction velocity depend weakly on analysis parameters, 
such as the extents in space and time of the local polynomial fit. Results from simulations 
with resolution and surface parameters similar to experiment, were used to choose 
parameters for analysis of experimental data. In the simulation, deviations from exact speed 
can be tracked. The deviations first decrease, and then increase as the spatial extent of fitting 
region increases. Figure 4B shows the normalized error of conduction velocity at different 
spatial and temporal extent of the fitting region. Values for the space and time windows that 
correspond to the lowest error in simulation were chosen. Note that this non-ideal 
dependence of velocity estimates on fitting parameters would be reduced if temporal and 
spatial resolution of activation times were increased significantly. In summary, we found the 
values of time window and space window that produced the lowest errors in our simulations, 
and used them for our experimental data set.  
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The accuracy of the conduction velocity estimation depends on the polynomial fitting of 
activation time  ,t   . Polynomial fitting eliminates the inaccuracy due to the noise or 
insufficient resolution by its smoothing effect. This explains why the normalized error 
initially decreases when the space window increases in Figure 4B. On the other hand, the 
error increases when  ,t    is not well fitted. This happens when large space window 
and/or time window are chosen. This is evident from Figure 4B that the normalized error 
starts to increase monotonically as space window becomes larger than certain value. 
 
Figure 9. Conduction velocity in epicardium during pacing. (A) Conduction velocity vectors after epicardial 
pacing. The activation isochrones has an interval of 2ms. (B) Anatomy and snapshot of transmembrane 
voltage. (C) Conduction velocity versus angles of conduction velocity. The angle of zero corresponds to the 
direction pointing to right. Angle increases in the counterclockwise manner. The yellow bar represents the 
condition when curvature of the surface is accounted for during the calculation of conduction velocity, while 
green bar is the opposite case. 
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    Figure 9A shows result of application of our method during epicardial pacing. The 
isochrones and conduction velocity vectors (red arrows) are shown. A snapshot of 
transmembrane voltage and anatomy are in Fig. 9B. Because of anisotropic conductance, the 
conduction velocity distribution over various angles has a sinusoidal shape (yellow bars in 
Fig. 9C). The peak value corresponds to the conduction velocity parallel to fibers; and the 
minimum value corresponds to the conduction velocity perpendicular to the fiber direction.  
    Figure 9C also shows the effect of surface curvature on the conduction velocity. If we 
simplify the calculation by assuming that all signals come from a focal plane, the resultant 
conduction velocity distribution will be like that in green bars. The green bars are generally 
shorter than the yellow bar, especially at the peaks. This means that the conduction velocity 
is underestimated when the velocity component normal to the plane is ignored. Since peak 
conduction velocity appears more on the edges of the field of view, where surface curves 
away, the deviations of peak conduction velocity is usually more significant. We quantified 
the effects of curvature in four hearts on the ratio of conduction velocity along longitudinal 
and transverse direction. The ratio is 2.45 ± 0.78 when no curvature is considered, different 
from the ratio 2.98 ± 0.84 when curvature is considered. The ratio is underestimated 
approximately by 17.8% if the curvature is not considered.  
This method can also be applied to reentrant activity during arrhythmia, i.e. ventricular 
tachycardia, when the conduction is mostly parallel to the epicardium. Figure 10 shows the 
conduction velocity vectors during stable reentrant spiral waves around a line of block.  
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Figure 10. Epicardial conduction velocity during reentry. Wave propagates around a line of block which is 
represented by clustered isochrones. The interval of activation isochrones is 2ms. 
 
2.5 Discussion 
In this paper, we presented methods to quantify the panoramic imaging data sets which have 
not been systematically presented before. We first transformed the mapping data from three 
PDAs into one 2D array, and then implemented quantitative analysis including dV/dt map, 
phase map, activation map and electric stimulus induced VEP map. We also adapted the 
method of Bayly et al. (11) for conduction velocity to the panoramic data sets. This method 
is tested on simulated, radially-propagating waves on a spherical surface. 
    Rogers (223) introduced anther framework for analysis of panoramic data sets by allowing 
locating phase singularity in an unstructured triangular mesh. This method is more general 
and works on the complex geometry. Our method, on the other hand, takes advantage of 
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simple geometry of the ventricles and simplicity of grid data set. It is simpler to implement 
and computationally less expensive.  
    All the methods mentioned in this paper can be implemented within a reasonable time 
period during experiment. Once silhouette images are obtained, a low resolution (e.g. 2mm) 
heart surface geometry can be obtained in about 20 seconds on a Windows PC (Pentium (R) 
4, 3.19 GHz CPU, 1.99 GB of RAM) using Matlab 7.0.1 (The Mathworks, Natick, MA).  
Higher resolution (e.g. 1mm) reconstruction takes about 75 seconds.  The user must 
manually register the heart surface to each PDA field of view, which takes approximately 
5~10 minutes.  Then, the heart geometry can be saved and used for texture mapping.  This 
fast and convenient method allows us to reconstruct and analyze every heart mapped in a 
reasonable amount of time.  
    The panoramic imaging setup optically mapped almost all the regions of the ventricles and 
parts of the atria. It should be noted that the spatial resolution at the tip of the apex can be 
low since the bottom curves away from every PDA. For the same reason, the spatial 
resolution is low at the edges of the field of view of every PDA. However, signals generated 
by these side regions are always simultaneously captured by two PDAs. As a result, sufficient 
resolution and signal to noise ratio can be restored from signals recorded from two PDAs 
(213).  
    Epicardial conduction velocities can be quantified on nearly the entire ventricular 
epicardium. However, caution needs to be taken to interpret the conduction velocity because 
conduction is three-dimensional in nature. The apparent epicardial conduction velocity is an 
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accurate representation of actual conduction velocity only when the wavefront propagates 
nearly parallel to the epicardial surface.  
    The analysis of panoramic mapping data introduced here enhances our ability to 
investigate the electrophysiology and non-linear dynamics of the heart. This provides an 
improved global perspective from which to investigate the cardiac conduction in normal and 
diseased conditions.  
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3. The Role Of Dynamic Instability And 
Wavelength In Arrhythmia Maintenance Revealed 
By Panoramic Optical Imaging With Blebbistatin 
Versus 2,3-Butanedione Monoxime 
3.1 Abstract 
Unlike other excitation-contraction uncouplers, blebbistatin has few electrophysiological side 
effects, and has gained increasing acceptance as an excitation-contraction uncoupler in 
optical mapping experiments. However, the possible role of blebbistatin in ventricular 
arrhythmia has hitherto been unknown. Furthermore, experiments with blebbistatin and 2,3-
butanedione monoxime (BDM) offer an opportunity to assess the contribution of dynamic 
instability and wavelength of impulse propagation to the induction and maintenance of 
ventricular arrhythmia.  
    Recordings of monophasic action potentials were used to assess effects of blebbistatin in 
Langendorff-perfused rabbit hearts (n = 5). Additionally, panoramic optical mapping 
experiments were conducted in rabbit hearts (n = 7) which were sequentially perfused with 
BDM, then washed out, and subsequently perfused with blebbistatin. The susceptibility to 
arrhythmia was investigated using shock-on-T protocol. We found that (i) application of 
blebbistatin did not change action potential duration (APD) restitution; (ii) in contrast to 
blebbistatin, BDM flattened APD restitution curve and reduced the wavelength; (iii) 
incidence of sustained arrhythmia was much lower under blebbistatin than under BDM 
(2/123 vs. 23/99). While arrhythmias under BDM were able to stabilize, the arrhythmias 
under blebbistatin were unstable and terminated spontaneously. 
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    In conclusion, the lower susceptibility to arrhythmia under blebbistatin than under BDM 
indicates that blebbistatin has less effects on arrhythmia dynamics. A steep restitution slope 
under blebbistatin is associated with higher dynamic instability, manifested by the higher 
incidence of not only wave breaks but also wave extinctions. This relatively high dynamic 
instability leads to the self-termination of arrhythmia, because of the sufficiently long 
wavelength under blebbistatin.   
3.2 Introduction 
Optical imaging techniques have been widely used to study the cardiac electrophysiology in 
species ranging from embryonic zebrafish to human beings (68, 89, 126). Optical mapping 
offers several important advantages over alternative mapping techniques: easily adjustable 
high spatial resolution, no physical contact with the tissue, absence of stimulation artifacts, 
and the capacity to simultaneously map different physiological parameters (68). Despite 
these advantages, optical mapping suffers from the need to utilize excitation-contraction (EC) 
uncouplers in order to remove motion artifacts from the optically recorded signals. 
Unfortunately, most of these uncouplers have electrophysiological side effects. For example, 
a popular inexpensive uncoupler 2,3-butanedione monoxime (BDM) results in changes of 
the action potential (AP) and conduction velocity (CV) in a species-dependant manner by 
affecting the ion channels, Ca2+ handling, and gap junctional coupling (46, 158, 226, 251, 
258). Another EC uncoupler, Cytochalasin D, also changes AP morphology (8, 22, 39) by 
affecting various ion channels (170, 188, 219, 244).  
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    Our group has previously shown that blebbistatin could completely eliminate mechanical 
contraction without appreciable electrophysiological effects on AP morphology, ECG 
parameters, conduction, and refractoriness in the rabbit heart (76). Following this 
introduction of blebbistatin as an EC uncoupler (76), it has increasingly gained popularity in 
cardiac electrophysiological studies. As of today, it was successfully applied in optical 
mapping studies of the hearts from embryonic zebrafish (120), mouse (61), rabbit (76, 176, 
191), dog (78, 129), horse (80), and the human beings (73, 74, 89, 159).  
    Both BDM and cytochalasin D were found to affect the vulnerability to ventricular 
arrhythmias (39) and the pattern of ventricular fibrillation (110, 143, 221). However, the 
effect of blebbistatin on ventricular arrhythmia is unknown. The aim of this study was to 
determine the vulnerability and characteristics of shock-on-T-induced arrhythmias under 
blebbistatin compared with BDM. Since shock-induced arrhythmia typically self-terminates 
in normal rabbit hearts in vivo (167) and in vitro (39) in the absence of EC uncoupler, we 
hypothesized that sustainability of shock-induced arrhythmia will be lower under blebbistatin 
versus BDM.  
3.3 Methods 
3.3.1 Experimental protocols 
New Zealand White rabbit hearts (n = 12, 4 months old) were Langendorff-perfused with 
oxygenated 37 °C Tyrode’s solution as previously described (161, 214). In the first set of 
experiments (n = 5), we recorded monophasic action potentials (MAP) using a MAP 
electrode (Harvard Apparatus, Holliston, MA) under control condition (i.e., no drug) and 
under 10µM blebbistatin. We applied the S1S2 ventricular pacing protocol consisting of an 
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initial train of 15 S1 stimuli with an S1-S1 interval of 300ms followed by a single S2 stimulus. 
We gradually decreased the S1-S2 interval from 400ms to the refractory period. Pacing 
current was adjusted to twice the pacing threshold. Continuous MAP recordings were 
maintained under both conditions. No voltage-sensitive dye was used in this part of the 
study. 
  In the second set of experiments (n = 7), the heart was stained with di-4-ANEPPS 
(20~40μL of 1.25mg/ml, Invitrogen, Carlsbad, CA). The heart was perfused in the following 
sequence: (1) Tyrode’s solution with 15mM BDM (Fisher Scientific, Hampton, NH); (2) 
Tyrode’s solution alone to wash out the BDM; (3) Tyrode’s solution with 10µM blebbistatin 
(Tocris Bioscience, Ellisville, MO). The S1S2 pacing protocol and vulnerability grid 
measurement for shock-induced arrhythmia were conducted under both BDM and 
blebbistatin.  
    The same S1S2 pacing protocol used in the first experimental set was applied for the 
quantification of APD restitution and CV restitution. The bipolar pacing electrode was 
placed epicardially in the center of the anterior view of the heart to allow the measurement 
of the CV in both longitudinal and transverse directions of the fiber orientation, as described 
earlier (162, 214).  
    The vulnerability to shock-induced arrhythmia was quantified using the vulnerability grid 
(70, 148), in which inducibility of arrhythmia was determined for varying shock strengths (2 - 
14 V/cm) and varying coupling intervals spanning the T-wave (equivalently, 70% - 140% of 
the averaged APD). Uniform far-field square monophasic shocks (10ms in duration) were 
delivered via two mesh electrodes on opposite sides of the heart (63, 148) after a train of 15 
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stimuli with S1-S1 interval of 300 ms and varying coupling interval between the last S1 and 
the shock. The arrhythmia was  categorized as "nonsustained" if it lasted >6 beats but ≤1 
min after the shock. The arrhythmia was defined as ―sustained‖ if it lasted for >1 min, which 
always required a defibrillation shock for termination. To avoid excessive shocks applied to 
the heart, the vulnerability grid was tested for just one polarity configuration where the mesh 
electrode facing the right ventricle (RV) was the cathode and the mesh facing the left 
ventricle (LV) was the anode.  
3.3.2 Optical imaging system 
The panoramic optical imaging system could record the optical AP from almost the entire 
ventricular epicardium of the rabbit heart (149, 222). Details of the panoramic imaging 
system and corresponding data analysis methods have been described earlier (162, 214). This 
system, including three photo-diode arrays (PDAs), optically maps the action potentials at 
three different angles (120° apart). In order to combine the data from three PDAs into one 
unified surface, the epicardial three-dimensional surface of every experimented rabbit heart 
was first reconstructed from 36  silhouette images of that heart. The optical signals were 
then registered onto the reconstructed surface. After that, various parameters, including 
APD, CV, wavelength (APD × CV) and wave propagation, were quantified and can be 
visualized on the reconstructed surface. To characterize Winfree’s ―elbow room‖ needed for 
reentry to sustain, we introduce a new factor - wavelength surface area, computed as the 
product of longitudinal and transverse wavelengths. 
3.3.3 Data analysis 
The APD was measured at 80% repolarization (APD80). The longitudinal and transverse 
CVs were measured near the pacing site at the epicardial surface. The phase was calculated 
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by Bray's method (30) and was used to visualize the wavefronts and phase singularities 
during reentrant arrhythmias. Comparisons were made between results under blebbistatin 
and BDM, as well as between control and blebbistatin. The Student’s paired t-test was used 
to determine the level of statistical significance. P<0.05 was considered statistically 
significant. Values were given as means ± S.D. 
3.2 Results 
3.2.1 Monophasic action potential with and without blebbistatin 
To determine the effects of blebbistatin on the AP morphology and APD, the MAP were 
recorded before and after the application of blebbistatin under multiple pacing rates. We did 
not detect significant differences between the control and blebbistatin in the measurement of 
APD. Figure 11 shows representative MAP recordings (Fig.11A) and the statistical summary 
(Fig.11B). The overlap between the MAP recordings and ECG for the control (blue color) 
and blebbistatin (red color) in Fig.11A indicates no change of AP morphology after the 
application of blebbistatin. This is further demonstrated in the summary in Fig.11B, which 
showed no significant effects of blebbistatin on APD.  
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Figure 11. Monophasic action potential (MAP) recordings. (A) Representative MAP and ECG recordings 
for S1S2 = 300ms and 200ms. (B) Summary of MAP durations at 80% repolarization (MAPD80) at 
various S1S2s. MAPD80 was not significantly changed under blebbistatin.  
 
3.2.2 Vulnerability to shock-induced ventricular tachyarrhythmia   
Figure 12 shows the arrhythmic incidence at different shock strengths and various coupling 
intervals under BDM (Fig.12A-Left) and blebbistatin (Fig.12A-Right). In total, 99 shocks 
were applied under BDM and 123 shocks were applied under blebbistatin in all hearts. The 
overall incidence of arrhythmia (including both nonsustained and sustained arrhythmia) was 
38/99 under BDM and 33/123 under blebbistation (Fig.12A-Top row). On average, the 
incidence was significantly  lower under blebbistatin (27±12% under blebbistatin versus 
51±20% under BDM, p = 0.046, Fig.12B ). Furthermore, the total incidence of sustained 
arrhythmia is 23/99 under BDM and 2/123 under blebbistatin (Fig.12A-Bottom row). That is, 
the average probability of sustained arrhythmia under blebbistatin was drastically lower than 
under BDM (1±4% under blebbistatin versus 30±14% under BDM, p = 0.001, Fig.12B). 
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Figure 12. Vulnerability grid and incidence of shock-induced arrhythmia. (A) Vulnerability grid with the 
inducibility of arrhythmia shown for various shock strengths and coupling intervals for both BDM (left, n=7) 
and blebbistatin (right, n=7). The top row shows the incidence of nonsustained and sustained arrhythmia 
combined. The bottom row shows the incidence of sustained arrhythmia only. It can be seen that the 
inducibility of sustained arrhythmia is significantly lower under blebbistatin (23/99 under BDM vs. 2/123 
under blebbistatin). (B) Summary of the incidence of shock-induced arrhythmia. 
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Figure 13. Induction of arrhythimia by a T-wave shock. (A) Representative action potential recordings with 
shock marked by the orange stripe. (B) The virtual electrode polarization pattern induced by a 10 V/cm 
shock at a coupling interval of 160ms. The red color indicates the positive polarity (virtual cathode); the blue 
color indicates the negative polarity (virtual anode). (C) Post-shock activation snapshots with the end of shock 
indicated by 0ms. The shock-induced wavefront initiates from the border between positive and negative virtual 
electrode polarization and propagates in the form of figure-of-8 reentry.  
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3.2.3 Induction of arrhythmia 
The induction of arrhythmias was similar under both conditions and was due to a well-
established mechanism termed virtual electrode-induced phase singularity (65). Figure 13 
shows a representative example of arrhythmia induction (under BDM). Essentially, the far-
field shocks produced spatially heterogeneous virtual electrode polarizations at different 
regions of the heart (Fig.13A&B), consisting of a virtual anode (blue) and a virtual cathode 
(red). Fig.13C shows a sequence of snapshots of activation wavefronts (dark red) over the 
course of arrhythmia induction, starting immediately after the shock. A wavefront of 
excitation arises at the boundary between the virtual cathode and the virtual anode via the 
break-excitation mechanism (see emerging red area in the snapshots for 10ms and 30ms at 
Fig.13C). Then it spreads to the de-excited region of the virtual anode, leading to the 
initiation of reentrant arrhythmia maintained by two phase singularities with opposite 
topological charges. Phase singularities are seen in Fig.13C as points where all phases, 
represented by different colors, converge.   
3.2.4 Stabilization of arrhythmia under BDM 
In the beginning of the shock-induced reentrant arrhythmia, the phase singularity (or 
singularities) of the reentry was (were) mostly not stable and were meandering under both 
BDM and blebbistatin. Differing from the arrhythmia under blebbistatin, phase singularities 
under BDM were much more likely to stabilize and stop meandering. This difference is 
indicated by the dramatic difference in the incidence of sustained arrhythmia (Fig.12). 
Fig.14A shows an example, with the snapshots of wavefronts (dark red) showing the steps 
of the stabilization of the reentry under BDM. In the first beat, there are multiple lines of 
conduction blocks, indicated by the crowded isochrones. The number of conduction blocks 
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is reduced to one in the 2nd beat since we know that the left side connects with the right 
side in that unwrapped map. After that, this line of conduction block starts to shrink until 
the reentry has stabilized (3rd to 8th beats). 
 
Figure 14. Stabilization and anchoring of reentry under BDM. (A) Stabilization of a meandering wave to 
stable reentry under BDM. Activation maps of eight consecutive beats before the stabilization of the single 
reentry. The activation is from blue to red with 2 ms interval between two neighboring isochrones. (B) 
Summery of the anchoring sites of stable reentry under BDM. Three different views from left to right: view 
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toward RV free wall, anterior view of the heart with left anterior descending coronary artery sketched, view 
toward LV free wall. The anchoring sites for each heart are shown with each color corresponding to one heart. 
The area of RV insertion to the septum is shown in gray color in those three views as well as in a cross-
section shown on the right.  
 
We observed 17 morphologies of stable reentries, with each having a single or double phase 
singularity (or singularities) at the epicardium under BDM. The locations of all phase 
singularities from seven hearts are summarized in Figure 14B at three different views 
(anterior, RV, and LV). It can be seen that the anchoring of reentry was geometrically 
asymmetrical, with the highest probability at the gray area in Fig.14B, where RV inserts into 
the septum and LV. Less frequently, the reentry anchored at the apex or at the RV freewall 
(Fig.14B). Interestingly, no epicardial anchoring at the LV was observed.  
3.2.5 Unstable maintenance and self-termination under blebbistatin 
Despite a similar mechanism of arrhythmogenesis, the dynamic maintenance of shock-
induced arrhythmia was different under blebbistatin. Similar to the in vivo observations (167), 
more than 98% of the shock-induced arrhythmia self-terminated under blebbistatin within 
one minute. Wave breaks and wave collisions were common, and the wave propagation was 
unstable with beat-to-beat variations under blebbistatin. Figure 15 shows snapshots of wave 
propagations under BDM (Fig.15A) and blebbistatin (Fig.15B) in the same heart. It can be 
seen that the reentry under both conditions anchors at the apex of the heart. Despite the 
similarity in the anchoring site, the regularity or stability of reentry differs under these two 
conditions. The bottom-right plot in each panel shows the activation sequence of all the 
recorded epicardial sites over the course of three consecutive beats. That is, each green dot 
in this panel indicates the activation of a particular mesh element (y-axis) at a particular time 
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(x-axis). The repeatability of the activation pattern for every beat shown in Fig.15A-Bottom 
right indicates the regular and stable conduction under BDM. On the other hand, small local 
conduction blocks (arrows in Fig.15B) were frequent under blebbistatin. Fig.15B-Bottom right 
shows the beat-to-beat variation in propagation. The holes within the green stripes in 
Fig.15B-Bottom right indicate the local wave breaks and subsequent wave extinctions (or 
collisions) . While the stable reentry under BDM was terminated by a defibrillation shock, 
the unstable reentry under blebbistatin self-terminated during the intermission between two 
consecutive data acquisitions. 
  Figure 16 is an example of self-termination of an unstable figure-of-8 reentry under 
blebbistatin, which was anchored at two phase singularities (white dots). Fig. 16A is an AP 
recording over the course of pacing, shock, arrhythmia, and self-termination. Fig. 16B shows 
phase maps (in polar view with the apex in the center) indicating the two phase singularities 
with opposite topological charges induced by the shock. It is clear that the locations of phase 
singularities gradually changed over time. The reentry self-terminated due to the collision 
and annihilation of two phase singularities in the last beat. Fig.16C-E are several other 
snapshots of activation in the same recording, and shows two characteristics of reentry 
frequently observed under blebbistatin but not under BDM. One characteristics is the ―stop-
sign phenomenon‖, during which the wavefront appears to stop for a while and then 
continues from where it stopped (Fig.16C). This behavior is also evident from the temporal 
gaps between activations from all mapped areas on the epicardium (Fig.16D). Another 
characteristics is that a breakthrough often appears ahead of the wavefront (Fig.16E). Both 
characteristics suggest the presence of transmural activations. 
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Figure 15. The stability of reentrant arrhythmia under BDM (A) and blebbistatin (B) in one heart. A 
representative action potential recording is shown on the top of each panel. Phase maps within a cycle of 
reentry are shown in each panel with the view toward the apex of the heart. The white arrows shown in the 
phase maps for blebbistatin point out transient conduction blocks, which were frequently observed under 
blebbistatin. It can be seen that both reentries anchor at the apex of the heart. While the reentry last under 
BDM, the reentry terminated spontaneously under blebbistatin. The activation pattern of three consecutive 
beats is plotted on the bottom right of each panel, with each green dot indicating an activation of every 
individual element of the meshed surface. The beat-to-beat variation is evident from the plot for blebbistatin.  
 
3.2.6 APD and CV restitution and wavelength 
Fig.17A shows representative optical AP recordings, and Fig.17C-top summarizes APD 
restitution curves under blebbistatin and BDM. Fig.17B shows representative activation 
maps, and Fig.17C-middle shows CV restitution curves along both longitudinal and transverse 
directions under blebbistatin and BDM. As expected, the APD was shorter and the APD 
restitution curve was flatter under BDM; the CV was slower under BDM in both directions. 
Wavelength was computed for longitudinal and transverse conduction and was significantly 
longer under blebbistatin than BDM (Fig.17C-bottom). At different cycle lengths, the 
wavelength surface area, which is a simple estimation of area needed for sustaining reentry, 
ranged from 19~34 cm2 under BDM and 39~60 cm2 under blebbistatin. The average 
ventricular epicardial surface area was 39.4±4.9 cm2 (n=7), which was well above the 
wavelength surface area of BDM but close to or below the wavelength surface area of 
blebbistatin.  
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Figure 16. Self-termination of reentry under blebbistatin. (A) A representative action potential recording. Shock is 
indicated by the orange stripe. (B) Phase maps from 12 consecutive beats (time points indicated by the asterisks in 
panel A) with phase singularity indicated by white dots. The map is shown in polar form with apex in the center. It is 
evident that the pivots of figure-of-8 reentry meanders overtime. The collision of the two phase singularities with opposite 
topological charge led to the termination of arrhythmia. (C) Wave front and tail collision. Three consecutive phase maps 
shows that the wavefront stops for 45 ms before it continues. (D) The activation plot with each dot corresponding to an 
activation of one pixel. Each pixel is coded with an unique color. The y-axis is the cycle length. The gray stripes 
indicate the gap where no epicardial activation is observed and correspond to the wave front and tail collision seen in the 
panel C. (E) Breakthrough excitation ahead of the wavefront. Three consecutive phase maps are shown with the 
breakthrough excitation (indicated by the white asterisk) visible on the second one. 
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Figure 17. Comparison of action potential duration (APD) restitution, conduction velocity (CV) restitution, and 
wavelength (APD × CV) between blebbistatin and BDM. (A) Representative AP recordings under blebbistatin (red) 
and BDM (62) at various S1S2 coupling intervals. (B) Representative activation maps under BDM and blebbistatin 
for both anterior and posterior view of the heart. (C) .(C) APD, CV and wavelength at varying cycle lengths. CV and 
Wavelength are shown for both longitudinal and transverse conduction. It can be seen that BDM significantly decreases 
APD and flattens APD restitution, significantly reduces CV and wavelength on both longitudinal and transverse 
direction 
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3.3 Discussion  
In this study, we investigated the effect of blebbistatin on the vulnerability to shock-induced 
ventricular arrhythmias in the normal rabbit heart. We found that (1) APD restitution under 
blebbistatin was not significantly different from the control condition, (2) BDM significantly 
reduced APD, CV, and wavelength; and flattened APD restitution, and (3) the sustainability 
to shock-induced arrhythmia was much lower under blebbistatin (2/123) than under BDM 
(23/99). These results showed that blebbistatin did not affect the vulnerability to shock-
induced arrhythmia and suggested blebbistatin as a superior EC uncoupler to BDM in the 
arrhythmia studies using optical mapping. In addition, both dynamic instability and 
wavelength appear to contribute to the self-termination of arrhythmia under blebbistatin, 
and therefore explain the lower susceptibility to sustaining arrhythmia under blebbistatin 
than under BDM. 
3.3.1 Effect of blebbistatin on electrophysiology 
It has been previously shown that the ventricular arrhythmia in the normal rabbit heart is 
prone to self-termination (12, 39, 167). The resistance to sustained arrhythmia under 
blebbistatin observed in this study suggests the preservation of normal electrophysiology by 
blebbistatin. We did not observe any changes of ventricular AP morphology under 
blebbistatin, which is consistent with other studies in the rabbit heart (76, 125), mouse heart 
(61), embryonic zebrafish heart (120), and equine heart (80). Taken together, these results 
suggest insignificant electrophysiological side effects of blebbistatin.  
    While blebbistatin appears to be a ―clean‖ drug for the normal heart, whether blebbistatin 
changes the electrophysiology in the diseased heart remains to be determined. Blebbistatin 
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inhibits myosin ATPase and thus prevents a significant amount of ATP from being 
consumed by mechanical contractions, making it available to electrogenic pumps. This effect 
could enhance the metabolic state of excitation and calcium handling in a diseased heart. 
Baudenbacher et al. (10) showed that Ca2+ desensitization of myofilaments by blebbistatin 
could reduce the arrhythmia in transgenic mice expressing troponin-T mutations. By 
inhibiting the contraction, blebbistatin could also prevent sarcolemmal rupture and cell death 
by reducing the mechanical stress occurring at the onset of reperfusion after ischemia (87, 
116). These protective effects of blebbistatin suggest that caution should be taken in 
applying blebbistatin when studying diseased heart. 
3.3.2 Functional reentry in the rabbit heart 
Since there is no structural obstacle (such as myocardial infarction scar) in these normal 
rabbit hearts, the anchoring of reentry under BDM is achieved at the normal anatomical 
structures. This observation suggest that an abnormal structure is not necessary for 
sustaining the arrhythmia. The observed asymmetrical distribution of anchoring points of 
stable reentrant arrhythmia (Fig.14B) indicates that the anterior RV insertion area (gray area 
in Fig.14B) is the most favorable area for anchoring. A computer simulation study by Park et 
al. (199) also identified the anterior RV insertion area as a distinct substrate for arrhythmia. 
In their whole rabbit ventricular model with global reduction of Na+ currents (199), they 
found that the RV insertion area was more susceptible to arrhythmia because of a source-
sink mismatch in the RV insertion area (199).   
    These results suggest that global electrical remodeling does not necessarily lead to a 
spatially homogeneous increase in the arrhythmia susceptibility. Washout of BDM and 
application of blebbistatin in our study almost completely abolished the maintenance of 
43 
 
ventricular arrhythmia, suggesting that idiopathic ventricular tachycardia with normal heart 
structure might respond well with pharmacological intervention, despite the presence of 
several preferential anchoring points of reentry.  
3.3.3 Dynamic instability under blebbistatin 
According to the computer simulations, steep APD restitution is associated with enhanced 
dynamic instability (36, 193, 216, 218). This association could partially explain the more 
unstable wave dynamics under blebbistatin than under BDM. The instability of wave 
propagation under blebbistatin was reflected by frequent wave breaks and wave extinctions. 
The dynamic instability is further reflected by the frequent occurrence of breakthrough 
excitation ahead of the reentrant wavefront under blebbistatin (Fig.16E). This type of 
breakthrough excitation on the surface of 3D tissue has been previously observed in an 
elegant computer simulation study of scroll wave dynamics by Qu et al. (216), who 
demonstrated correlation between the breakthrough activity with the strong dynamic 
instability. In a 3D tissue like the rabbit heart in this study, a scroll wave faces excitable tissue 
not only in its own layer but also in the neighboring layers. According to the simulation (216), 
the strong dynamic instability and fiber orientations could result in different speed of spiral 
waves at different layers of the tissue. When the spiral wave at a depth (or intramural 
conduction) is faster than the spiral wave on the surface, an upward propagation towards the 
epicardial surface could occur and thus produce the breakthrough excitation on the 
epicardial surface. The "first stop, and then continue" wavefront (Fig.16C) observed under 
blebbistatin also suggests the presence of intramural conduction connecting the epicardial 
activation gaps (Fig.16D).  
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3.3.4 Dynamic instability and self-termination of arrhythmia 
Dynamic instability alone is not sufficient to prevent the maintenance of arrhythmias. Mines 
(175) and Garrey (88) postulated that the wavelength in comparison to tissue size is the 
major determinant of reentry maintenance. Numerous studies confirmed Mines and Garrey's 
theory. For example, Qu et al.'s simulation indicated that whether dynamic instability 
promotes or prevents the maintenance of arrhythmia depends on the effective tissue size, 
which is determined by the wavelength and the actual tissue size (215). This is supported by 
the experimental findings by Harada et al. (102). Compared with the control, severe 
hypothermia did not change the incidence of sustained arrhythmia despite a dramatic 
increase of dynamic instability, because severe hypothermia decreased the wavelength (102). 
On the other hand, mild hypothermia did not alter the wavelength while it increased the 
dynamic instability, resulting in a significant reduction in the incidence of sustained 
arrhythmia (102). The limited tissue size versus longer wavelength under blebbistatin was 
evident from the wavefront and waveback collisions (Fig.16).  
    It is difficult to quantify the individual contribution of dynamic instability and wavelength 
in the maintenance of arrhythmia, because the experimental approach does not have the 
luxury to finely tweak the dynamic instability and effective tissue size in three dimensions as 
the computer simulations so elegantly do. Nevertheless, our results indicate the beneficial 
role of dynamic instability and wavelength combined in preventing the maintenance of 
arrhythmia.   
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3.4 Limitation 
There are limitations in this study. First, we could not measure the true wavelength during 
the arrhythmia, because the apparent epicardial CV might not reflect the true CV and the 
baseline (minimum of the signal) might not represent the resting state. Nevertheless, the 
wavelength surface area, which was calculated from wavelengths during pacing, works 
surprisingly well in predicting the sustainability of arrhythmia in this study. The second 
limitation is that reentry dynamics are only studied in the normal heart in this study. Caution 
is needed to extrapolate the results to diseased hearts. Third, the vulnerability of the heart to 
arrhythmia between the control condition and under blebbistatin are not compared in this 
study. However, low arrhythmia vulnerability is expected in the normal heart and has been 
demonstrated previously both in vivo and ex vivo (39, 167). Finally, we cannot exclude the 
effects of edema, which might develop in the mechanically silent preparations. 
  In conclusion, the low incidence of sustained arrhythmia and the preserved APD resitution 
under blebbistatin suggest blebbistatin as a superior EC uncoupler to BDM. The 
combination of dynamic instability and wavelength facilitates the spontaneous termination 
of arrhythmia.   
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4. The Susceptibility to Alternans is Enhanced in a 
Rabbit Model of Chronic Myocardial Infarction 
4.1 Abstract 
Repolarization alternans plays an important role in the genesis of deadly arrhythmia, 
especially in patients with chronic myocardial infarction. It remains elusive how the healed 
myocardial infarct contribute to the repolarization alternans and dispersion of repolarization.  
    In this study, we studied inducibility and dynamics of action potential duration (APD) 
alternans using optical mapping in a rabbit model of healed myocardial infarction 
(>3months, n=9) and control rabbit hearts (n=9). We observed that (1) spatially concordant 
APD alternans occurred at a significantly slower heart rate in infarcted heart with control 
hearts (294 ± 27 bpm vs. 369 ± 25 bpm, P < 0.001), (2) the pacing rate threshold for 
spatially discordant alternans also significantly decreased in the infarcted heart compared 
with control heart (366 ± 47 bpm vs. 458 ± 53 bpm, P = 0.014), (3) increased alternans 
susceptibility is closely associated with the infarct border zone, (4) dynamic APD restitution 
curve could not predict and always overestimate the pacing rate at the onset of APD 
alternans in the infarcted heart, (5) conduction velocity alternans proceeded the occurrence 
of spatially discordant alternans in the infarcted heart, and (6) there existed a distinct pattern 
spatially discordant alternans in the form of small islands in the infarct border zone.  
    In conclusions, healed myocardial infarction promotes repolarization alternans especially 
in the infarct border zone. The subsequent increase of  dispersion of repolarization could 
provide the substrate for the induction of ventricular arrhythmia.  
47 
 
4.2 Introduction 
Sudden cardiac death is a leading cause of death and is most commonly associated with 
ventricular arrhythmias (225). Healed myocardial infarction is present in approximately half 
of sudden cardiac death cases presenting ventricular fibrillation (238). Despite the prevalence 
of healed myocardial infarction in the cardiac arrest victims, there has been little study of 
arrhythmia mechanism in the setting of a healed myocardial scar. Better understanding of 
mechanism could facilitate the development of anti-arrhythmic therapies such as the novel 
gene therapy (227).  
    Several clinical  studies have identified reentry as the main mechanism for the ventricular 
tachycardia in the chronic phase of myocardial infarction (51, 261, 262). Using optical 
imaging technique, we have previously found that the maintenance of shock-induced 
ventricular tachycardia is closely associated the anchoring of mother rotors at the scar (148, 
149). Ohara et al. showed that increased dynamic instability in the healed infarct border zone 
lead to a higher wavelet density which sustained the ventricular fibrillation (196). Compared 
with the knowledge of arrhythmia maintenance in the heart with healed myocardial 
infarction, the induction of arrhythmia is less known.  
    T-wave alternans, reflecting the beat-to-beat repolarization alternation, was found 
clinically to be a predictive marker for sudden cardiac death in patients with healed 
myocardial infarction (115, 189). Narayan et al. (189) found that T-wave alternans was 
spatially correlated with the scar in those patients, suggesting infarct border zone as the 
substrate of the repolarization alternans. Optical mapping technique has greatly enhanced 
the mechanistic understanding of T-wave alternans (or repolarization alternans) and its 
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linkage to the induction of arrhythmia (44, 176, 200, 201, 212, 265). Pastore et al. (200) nicely 
demonstrated that close correspondence between T-wave alternans and alternans of action 
potentials duration (APD) in normal rabbit heart. They also showed that spatially discordant 
alternans (APD alternans being out of phase between neighboring cells) lead to conduction 
block against steep gradient of repolarization and thus the initiation of reentrant arrhythmia 
(200).  
    In this study, we aimed to use optical mapping technique to explore the susceptibility to 
repolarization alternans in a rabbit model of healed myocardial infarction (>3 months), to 
determine the spatial correlation between alternans-susceptible regions and the scar, and to 
examine the contribution of APD restitution and conduction velocity alternans in the APD 
alternans in producing the APD alternans.  
4.3 Methods 
The experimental protocol was approved by the Institutional Animal Care and Use 
Committee of Washington University in St. Louis. New Zealand White rabbits (n=18) of 
either sex were used in this study. Half of the rabbits (n=9) underwent in vivo survival 
surgery as previously described (148, 149) to create chronic MI via ligation of a descending 
branch of the left circumflex artery. These rabbits were allowed to heal for at least 3 months 
before optical mapping experiments. The other half of the rabbits (n=9) were not subject to 
the surgery and were used as controls.  
    Rabbits were injected intravenously with sodium pentobarbital (50 mg/kg) and 1000-2000 
U heparin. Hearts were quickly excised, and then Langendorff-perfused with 37°C Tyrodes' 
solution (in mmol/l: 128.2 mM NaCl, 4.7 mM KCl, 1.19 NaH2PO4, 1.05 mM MgCl2, 1.3 mM 
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CaCl2, 20.0 mM NaHCO3, and 11.1 mM glucose, and gassed with 95% O2-5% CO2; 
pH=7.35±0.05) at an arterial pressure of 60–70 mmHg. The excitation-contraction 
uncoupler blebbistatin (10μM; TOCRIS) was added to the perfusate to suppress motion 
artifacts in optical recordings (76). The heart was stained with voltage sensitive dye RH237 
(Invitrogen, CA) for optical action potential (AP) measurement. Fluorescent signals were 
recorded by CMOS camera (SciMedia, CA).  
    Dynamic restitution protocol was conducted starting at a basic cycle length (BCL) of 
300ms. The heart was paced at the apical side of the right ventricle and optically mapped 
from the anterior surface.  The pacing interval was gradually decreased until the heart cannot 
be paced or arrhythmia was induced. APD was quantified at the 80% repolarization (APD80) 
at each pixel of the camera. Dynamic APD restitution curves were constructed by plotting 
APD80 against the preceding diastolic interval (DI) for each pacing rate. DI was measured 
by the time from the 80% repolarization to the upstroke of next AP. The restitution curve 
was constructed by fitting the measurement using a single exponential (i.e.,         
           , where  ,   and   were coefficients and obtained by nonlinear least-square fits) 
or using a biexponential function (i.e.,                             
           , where  ,   ,   ,   ,and    were coefficients and obtained by nonlinear 
least-square fits).  
    APD alternans was measured by ΔAPD (i.e, the difference in APD80 between two 
consecutive beats). The threshold of APD alternans was defined as the lowest pacing rate at 
which at least 10% of mapped region has APD alternans (i.e., ΔAPD ≥ 4ms). The spatial 
organization of APD alternans will be presented by alternans maps with positive values 
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color-coded by red, negative values color-coded by blue, and zero by white. Sometimes 
APD80 of certain region cannot be quantified during alternans if the upstroke occurs before 
the decline of the previous action potential to 80% repolarization. In such cases, this region 
was color-coded by the saturated colors (deep red or blue) in the alternans map. Activation 
cycle length (CL) is measured based on the time duration between two consecutive AP 
upstrokes at each pixel. Activation CL alternans was also measured to reveal the conduction 
alternans. It should be noted that activation CL is different from the BCL.  
    Comparison was made between infarction group and control group. Levels of significance 
were determined by a Student’s paired or unpaired t-test, where p<0.05 was considered 
statistically significant. Values were given as means ± S.D.   
4.4 Result 
4.4.1 Pacing Rate Threshold for APD alternans 
To quantify the susceptibility to the repolarization alternnas, the pacing rate threshold for 
spatially concordant APD alternans and spatially discordant APD alternans were quantified. 
The threshold for the concordant alternans was significantly decreased in the infarction 
group relative to control (294 ± 27 bpm vs. 369 ± 25 bpm, P < 0.001). Similarly, the 
threshold for discordant alternans was also significantly decreased in the infarction group 
(366 ± 47 bpm vs. 458 ± 53 bpm, P = 0.014). Figure 18A shows APD alternans maps of an 
infracted heart (top row) and a control heart (bottom row) at multiple BCLs. Note that APD 
alternans starts to appear at a much slower BCL in the infarcted heart (210 ms or 286 bpm) 
compared with the control heart (150 ms or 400 bpm, at which more arrhythmogenic 
spatially discordant alternans started to occur in the infarcted heart). Figure 18B shows 
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sample optical AP traces from these two hearts at the BCL of 150 ms, where the APD 
alternans was much more evident in the recording from infarcted heart compared with the 
control.  
 
Figure 18. APD alternans maps and traces in control and in a heart with healed myocardial infarction. (A) APD 
alternans maps at basic cycle length (BCL) of 210 ms, 200 ms, 180 ms and 150 ms in a heart with healed 
myocardial infarction (top row) and in control heart (bottom row). The myocardial infarct (MI) is indicated in the a 
phtograph of the heart. The color indicates ΔAPD of two consecutive beats. (B) Sample action potential recordings 
from these two hearts at the BCL of 150 ms. It is evident that the alternans of action potential duration is much 
stronger in the recording from the infarcted heart (left) compared to the control (right). 
 
    The susceptibility to repolarization alternans was not spatially homogeneous in both 
infarction and control group. In the control hearts, the APD alternans consistently appeared 
first in the left ventricle (Figure 19-top row with the solid black line indicating the location 
of left anterior descending coronary artery). In comparison, in the hearts with healed 
myocardial infarction, APD alternans appeared first in the infarct adjacent area or infarct 
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border zone (Figure 19-bottom row), suggesting myocytes close to the scar were more 
susceptible to repolarization alternans.   
 
Figure 19. APD alternans map at the onset of alternans in 6 control hearts (CT1-CT6, top row) and 6 infarcted 
hearts (MI1-MI6, bottom row). The left anterior descending coronary artery (LAD) is indicated in every map. The 
scar area is circled by the dashed line. 
 
4.4.2 Dynamic APD restitution and APD alternans 
APD alternans occurs when the pacing rate is faster than a critical pacing rate. According to 
the restitution hypothesis, APD restitution curve determines the dynamic instability and 
predicts the critical pacing rate for APD alternans when its slope is equal to one. To test 
whether the APD restitution curve could precisely predict the actual critical pacing rate, we 
compared the predicted value with the measured value.  
    We found that the predicted pacing rate threshold for APD alternans was always higher 
than the actual pacing rate threshold for APD alternans, especially in the infarcted heart. 
Figure 20A is a representative plot with measurement of APDs and DIs of two consecutive 
beats (circles and squares) at multiple pacing rates from an infarcted heart. The circle and 
square are connected by a green line if they were neighboring beats from the same recording. 
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The increased APD alternans at increasing pacing rate is evident by the gradual separation of 
the paired circle and square toward the bottom left corner of the plot. A close examination 
of the plot revealed that the separation of paired circle and square (or the incidence of APD 
alternans) starts at the cycle length of 230 ms (261 bpm).  
 
Figure 20. Inaccurate prediction of action potential duration (APD) alternans by dynamic APD restitution curve. 
(A) Dynamic APD restitution curve reconstructed from action potential recordings from one pixel of an infarcted heart. 
Measurement of APD and diastolic interval of two consecutive beats (red circle and blue square connected by a green 
line in the plot) at 13 different cycle lengths are plotted. The black line is the APD restitution curve reconstructed by a 
biexponential fitting. The purple line of slope -1 intersect with the APD restitution curve (black line) at a point where 
the slope is 1, and predict the alternans to occur beyond the cycle length of ~162ms. This prediction is much lower than 
the maximum of measured cycle length for APD alternans where the paired circle and square are not overlapped in the 
plot (230ms). (B) Summery of the measured APD alternans cycle length threshold minus predicted threshold from 
APD restitution curves reconstructed by a single exponential function (left) and a biexponential function. 
 
    Dynamic APD restitution curve (black line in Fig. 20A) was reconstructed by fitting the 
measurements (circles and squares) using a biexponential function in Fig. 20A. The slope of 
this dynamic restitution curve is equal to one at the crossing of the black line and the pink 
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line (slope of -1) in Fig. 20A, which is supposed to predict the onset of APD alternans at the 
cycle length of 162 ms (370 bpm) according to the restitution hypothesis. Compared with 
the measured threshold for APD alternans at 261 bpm, the predicted pacing rate threshold 
for the onset of APD alternans is much higher than the actual value, suggesting APD 
restitution alone does not predict the APD alternans. And this is especially true in the 
infarction group (Fig. 20B).  
4.4.3 Spatially Discordant Alternans 
 
Figure 21. Dynamics of spatially discordant alternans. (A) APD alternans maps at multiple basic cycle lengths from 
a control heart (top row) and a heart with healed myocardial infarction (MI, bottom row). Pacing sites are indicated by 
a pulse square in each map. The myocardial infarct is circled by a black dashed line. The white nodal line (without 
APD alternans) separates regions of opposite sequence of APD alternans. (B) Representative action potential 
recordings from three locations a, b and c (indicated in the bottom-left map in panel A) from the infarcted heart. 
 
Since dynamics of the nodal lines were shown to reflect the underlying mechanism of the 
formation of spatially discordant alternans (111), we quantified the movement of nodal lines 
in both control and infarcted heart. The top row in Figure 21A is a representative example 
of the control heart. The nodal lines correspond to the white region in the APD alternans 
maps. The first nodal line appeared close to the base of the right ventricle (i.e., the top-left 
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side of the map), and a second nodal line was later formed at a distal end from the pacing 
site. Both nodal lines gradually moved toward the apex as the pacing rate was increased. We 
consistently observed the movement of nodal lines towards the pacing site at increasing 
pacing rate, suggesting that engagement of CV restitution in the creation of spatially 
discordant alternans in the control heart (111, 176).  
    The bottom row of Figure 21A is a representative example of the infarcted heart. The 
myocardial infarct is circled by a dashed line. In the non-infarcted area, the behavior of the 
nodal line moves towards the pacing site and is very similar to the control heart. On the 
other hand, the dynamics of nodal lines appears to be different within the infarct border 
zone. Small islands with opposite sequence of alternans within the infarct border zone were 
observed (Fig. 21A-bottom row). These islands are small in size compared to that in non-
infarcted area or in control heart. AP recordings within the island (site c), close to the island 
(site b), and far from the island (site a) are shown in Figure 21B. Close examination reveals 
that the odd beats are morphologically very different at these three sites while even beats are 
similar, indicating a different type of spatially discordant alternans compared with the those 
observed in control and noninfarcted region. In addition, close examination of these 
recordings suggests that the difference in the odd beats appears to result from the depression 
of the AP plateau in the infarct border zone (site c). As shown in the bottom row of Figure 
21A, the island with out-of-phase alternans remained pinned in the same position as pacing 
rate increases, and gradually shrank and then disappeared. This unique island within the 
myocardial infarct region was observed in 3 out of 9 infracted hearts.  
    To further demonstrate the role of CV alternans in the induction of spatially discordant 
alternans, we quantified the activation CL alternans (representing the CV alternans) and 
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examined its temporal relation to the appearance of spatially discordant APD alternans in 2 
infarcted hearts. We found that the alternans of activation CL preceded the alternans of 
SDA in these two hearts (Fig. 22). Top row in Figure 22 shows the maps of activation CL 
alternans and the bottom row of Figure 22 shows maps of APD alternans. Left column in 
Figure 22A&B are the maps created from data recorded immediately after increasing the 
pacing rate (0 min), and the right column are from data recorded 2 minutes later. In both 
examples, the regions with significant activation CL alternans at 0 min is the same region 
(blue region) where regions of opposite sequence of APD alternans appears at 2 min.  
 
Figure 22. Activation cycle length alternans precedes the occurrence of APD alternans in the infarcted heart. (A) 
Activation cycle length (CL) map (top row) and APD alternans map (bottom row) immediately after the shortening of 
CL (0 min, left column) and 2 min after (right column). It can be seen that the region with strongest alternans in the 
activation CL map at 0 min (the up-left map) corresponds to the blue area in the APD alternans map at 2 min (the 
bottom-right map). (B) Example from another infarcted heart, which showed similar phenomenon as in panel A.   
 
57 
 
4.5 Discussion 
In the present study, we quantified the susceptibility to APD alternans in a rabbit model of 
healed myocardial infarction. The pacing rate threshold for APD alternans was significantly 
decreased for both spatially concordant and discordant alternans in the infarcted heart. This 
enhancement was most significant in the infarct border zone. Dynamic APD restitution 
could not predict the increased dynamic instability in the infarcted heart. Conduction 
velocity alternans plays an important role in producing spatially discordant alternans in both 
control and infarction group, while some unknown mechanism  is responsible for a distinct 
pattern of spatially discordant alternans within the infarct border zone.  
4.5.1 Mechanism of APD Alternans 
Steep APD restitution was hypothesized to produce APD alteranns (193). If APD is solely 
dependent on the preceding DI, APD alternans should start at the cycle length at which the 
APD restitution slope is equal to one. APD restitution has been quantified in canine heart 
with healed myocardial infarction (196) and patient with structural heart disease (SHD) (128), 
45% of which had old myocardial infarction. Ohara et al. (196) found that the DI range over 
which the dynamic restitution slope > 1 is significantly increased in the endocardial 
infarction border zone in the infarction group compared to the control group. Koller et al. 
(128) found a significantly earlier onset of alternans of monophasic APs in patients with 
SHD compared with patients without SHD. 
    This hypothesis is not confirmed in the present study because APD alternans occurred at 
a much slower heart rate than that predicted by the APD restitution, especially in the 
infarction group. This incapability of APD restitution in predicting APD alternans was also 
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observed in other studies (121, 212, 242), suggesting other mechanisms responsible for the 
induction of APD alternans. In isolated rabbit myocyte, Chudin et al. showed that the 
calcium transient alternans was not affected by the clamping the voltage with AP of fixed 
duration (43), suggesting the calcium transient alternans as the driving force for APD 
alternans via calcium-dependent ionic currents. The key role of calcium handling in alternans 
has been implicated in other experimental studies (91, 137, 212).  
    The remodeling of calcium handling in the presence of healed myocardial infarction has 
been described in several studies. Litwin et al. showed that (155) the rising time and 
declining time were significantly prolonged in the rats 6 weeks post myocardial infarction. 
Mackiewicz (165) showed moderate decrease of decay rate of calcium transient in rats with 3 
months post myocardial infarction, which suggest moderate functional change of 
sarcoplasmic reticulum calcium ATPase (SERCA) and sodium/calcium exchanger (NCX). 
However, Andriy et al. (13) did not observe any change on the calcium uptake by SERCA 
and calcium transport by NCX in the myocytes from dog with more than 4 weeks 
myocaridal infarct. They found that pacing rate threshold of APD alternans and calcium 
transient alternans was significantly reduced, and they attributed the decreased alternans 
threshold to leaky ryanodine receptors due to steeper dependence of sarcoplasmic reticulum 
(SR) calcium release on the SR calcium content.  
4.5.2 Mechanism of Spatially Discordant Alternans 
Spatially discordant alternans describes the presence of out-of-phase APD in neighboring 
regions and a large APD gradient across the nodal lines. Spatially discordant alternans 
increases the dispersion of repolarization and was observed to precede the induction of 
ventricular arrhythmias (130, 200). Computer simulations (216, 257) and an experimental 
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study (53) have shown that spatially discordant alternans could be induced in spatially 
homogeneous tissue through the interactions of APD restitution and CV restitution. In 
addition, it was suggested that functional heterogeneity (111, 257) and structural 
heterogeneity (59, 201) might facilitate the formation of spatially discordant alternans. it was 
not unclear whether dynamic or functional/structural heterogeneity is the dominant 
mechanism for the formation of spatially discordant alternans in the presence of healed 
myocardial infarction.  
    We showed that the pacing rate threshold for the spatially discordant alternans was 
decreased in the rabbit heart with healed myocardial infarction. This is in line with the 
decreased alternans threshold in the rabbit heart with structural barriers created by laser 
epicardial lesions (201), suggesting the cellular uncoupling as one of the underlying 
mechanisms for spatially discordant alternans. The tissue discontinuities caused by the 
cellular uncoupling were known to produce abnormal conduction velocity restitution (59), 
which could underlie the induction of spatially discordant alternans as shown in computer 
simulations (216). The dynamics of the nodal lines in the noninfarct region in our study 
indicated the CV alternans as the cause of the spatially discordant alternans. The underlying 
mechanism of the distinct island of spatially discordant alternans within the infarct border 
zone remains to be investigated. It might be explained by fibrolast-myocyte coupling which 
was shown to promote alternans at a slower heart rate (266) and by reduced electronic 
effects which was shown to facilitate alternans (41).  
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4.6 Limitations 
Despite that the pacing rate of pacing rate threshold in the heart with healed myocardial 
infarction was significantly compared with control, it remains higher than the regular heart 
rate of the rabbit. However, this pacing rate threshold for alternans might be lower in vivo 
and become close to the range of regular heart rate, because denervation in ex-vivo 
condition could decrease the level of adrenergic stimulation and thus reduce the incidence of 
APD alternans (52, 101). This hypothesis remains to be tested in future. 
    Another limitation is that only epicardial action potential were measured in the present 
study. It remains unknown whether the increased cellular uncoupling in the infarct border 
zone could promote transmurally discordant alternans at relatively slow heart rate.  
    We did not test other mechanisms that might promote the induction of arrhythmia in the 
presence of healed myocardial infarction. It remains to be determined how important the 
enhanced APD alternans due to myocardial infarction contribute to the arrhythmogenesis in 
vivo. To avoid a lengthy protocol, only dynamic pacing protocol was used. It is possible that 
single or multiple premature stimuli could produce significant APD alternans that might be 
responsible for the arrhythmogenesis in the infarcted heart (138, 139). Furthermore, 
blebbistatin was used to abolish the contraction to remove the motion artifact. It remains to 
be determined how the stretch at the boundary between viable tissue and non-contracting 
scar during contraction could contribute to the alternans of repolarization.  
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5. Remodeling and Dispersion of Repolarization in 
the Right Ventricle of Failing Human Heart 
5.1 Abstract 
Increased dispersion of repolarization was suggested to underlie the increased 
arrhythmogenesis in human heart failure (HF). However, we have recently found no 
evidence of increase in left ventricular transmural dispersion of repolarization in the failing 
human heart. In this study, we sought to determine whether dispersion of repolarization was 
enhanced across the endocardium of the right ventricle (RV) of the failing versus non-failing 
human heart.  
  RV free wall preparations were dissected from five failing and five nonfailing human hearts, 
cannulated and coronary-perfused. Optical mapping was conducted at the endocardium 
from a ~6.3 × 6.3 cm field of view. Action potential duration (APD), dispersion of APD, 
and conduction velocity (CV) were quantified for the basic cycle length ranging from the 
refractory period to 2000 ms. APD was significantly prolonged in the failing group as 
compared to the nonfailing group. Dispersion of APD was significantly increased in only 
three failing hearts. APD alternans was induced by rapid pacing only in these three failing 
hearts. CV was significantly slower in the failing group than in the nonfailing group. 
Arrhythmia was induced only in two failing hearts, which had an abnormally wide cycle-
length range with steep CV restitution and were among the three hearts with increased 
dispersion of repolarization.  
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  In conclusion, dispersion of repolarization could be enhanced due to heterogeneous 
prolongation of APD, enhanced APD alternans, and slower conduction in failing human 
heart. Arrhythmia in the failing human heart was closely associated with increased dispersion 
of APD, APD alternans, and abnormally steep CV restitution.   
5.2 Introduction 
Ventricular arrhythmia is common in patients with heart failure (HF) (83, 171). It 
significantly increases the risk of sudden cardiac death (171, 210), which accounts for more 
than half of the congestive HF-related deaths (83). Our limited understanding of 
mechanisms of arrhythmogenesis confined our ability to obviate the risk of sudden cardiac 
death of patients with HF.  
  Remodeling and dispersion of repolarization play important roles in arrhythmogenesis. 
Dispersion of repolarization represents the heterogeneous recovery of excitability in 
neighboring myocytes. Enhanced dispersion of repolarization increases the vulnerable 
window for unidirectional block by a single premature beat (217), and increases the 
likelihood of arrhythmia (5). Compelling experimental evidence has demonstrated the 
correlation between the enhanced dispersion of repolarization and increased susceptibility to 
arrhythmia (69, 93, 100, 134, 248). Clinical studies have also shown strong links between 
dispersion of QT interval (reflecting dispersion of repolarization (270)) and ventricular 
tachyarrhythmia in patient with HF (9, 86, 209). Since the action potential duration (APD) is 
mainly responsible for the repolarization, changes in APD reflect the remodeling of 
repolarization. An important question is how HF affects the regional differences in APD 
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(243). The answer to this question could help identify the origin of the increased dispersion 
of repolarization and the potential target for clinical intervention in HF patients.   
  Akar et al. demonstrated that heterogeneous prolongation of left ventricular APD caused 
increased dispersion of repolarization and arrhythmia in a dog model of tachypacing-induced 
HF (3). They found that transmural dispersion of repolarization was markedly augmented in 
the failing dog heart due to more pronounced prolongation of action potential (AP) at the 
mid-myocardial and endocardial layers. Enhanced ventricular transmural dispersion of 
repolarization was also observed in other animal models of heart diseases and closely 
associated with the development of reentrant arrhythmias (5). 
  Thus a number of animal models of HF provided evidence of mechanistic link between the 
enhanced transmural APD dispersion and increased arrhythmogenesis. Recently we used 
optical mapping to investigate APD dispersion in the failing human left ventricle (89). In 
contrast to previous findings in animal models of HF, we found no evidence of enhanced 
APD dispersion in the failing human left ventricle. On the contrary, we found that despite 
overall increase in APD, the transmural dispersion of repolarization was surprisingly reduced 
in the failing human heart (89). This reduction of transmural dispersion of repolarization was 
also observed in a mouse model of pressure-overload HF (253), in a study of a dog model of 
tachypacing-induced HF (146), and was confirmed in a more recent study of excitation-
contraction coupling in the failing human heart (159).  
  It has been shown that the dispersion of endocardial repolarization of right ventricle (RV) 
could be enhanced in patients with sustained ventricular tachycardia (179) and in patients 
with long QT syndrome (26). We hypothesized that RV endocardium undergoes remodeling 
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during HF, which increased dispersion of repolarization, prolongs APD, and slows the 
conduction velocity (CV). All these three changes could contribute to increased propensity 
to arrhythmia. To test this hypothesis we applied optical mapping of action potentials at a 
large area of RV endocardium, 63 mm by 63 mm. Then we quantified the dispersion of APD, 
and restitution properties of both APD and CV.  Arrhythmia inducibility was tested using 
rapid pacing. 
5.3 Methods  
The protocol of the study was approved by the Washington University Institutional Review 
Board. Failing human hearts were obtained during transplantation from Barnes-Jewish 
Hospital of Washington University in St. Louis, MO. Donor hearts were provided by Mid-
America Transplant Service (St. Louis, MO) and used as the nonfailing group. Both failing (n 
= 5) and nonfailing (n = 5) human hearts were optically mapped. Patient information is 
shown in Table 1.    
  Explanted hearts were cardioplegically arrested. Details of tissue harvest, vessel ligation, 
and coronary perfusion can be found in our previous publications (89, 159). During 
dissection, entire RV free wall was isolated and cannulated at the origin of the right coronary 
artery. Care was taken so that the tissues were not stretched when they were pinned down 
onto a silicon sheet. Tissue was immobilized by 10~20 µM blebbistatin to suppress the 
motion artifacts in optical recordings. Optical APs were recorded from the majority of RV 
endocardium (63 ± 7 mm by 63 ± 7 mm). We did not map the epicardium because the 
entire epicardium of the failing human heart was often covered by a layer of fat which 
prevented the recording of optical signals.  
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Table 1. Patient Information 
   # Group Gender Age Diagnosis 
1 Failing Male 53 Non-ischemic Cardiomyopathy 
2 Failing Male 55 Ischemic Cardiomyopahty 
3 Failing Female 67 Non-ischemic cardiomyopathy 
4 Failing Male 59 Non-ischemic cardiomyopathy 
5 Failing Female 53 Non-ischemic Cardiomyopathy 
6 Nonfailing Female 51 Cerebrovascular/Strock 
7 Nonfailing Male 31 Gunshot wound to the head 
8 Nonfailing Male 40 
Head Trauma, Motor Vehicle 
Accident 
9 Nonfailing Female 59 Cerebrovascular/Stroke 
10 Nonfailing Male 76 Cerebrovascular/Stroke 
 
  In order to measure the dynamics of dispersion of repolarization at different cycle lengths, 
we stimulated the isolated RV using steady-state pacing. We commenced pacing at a cycle 
length (CL) of 2000 ms, and then gradually decreased CL until reaching refractory period or 
arrhythmia was induced. All the preparations were stimulated at the bottom of the field of 
view (close to the apex) at the voltage double the pacing threshold. Figure 23 shows a 
representative RV preparation and AP recordings from a nonfailing human heart. The APD 
was the duration from the upstroke (maximum derivative of the signal) to the 80% 
repolarization (APD80), and was measured at all recording sites. Global CV across the field 
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of view was also quantified at different cycle lengths. Dispersion of APD was quantified by 
the difference between 95th percentile and 5th percentile of APD80 from all the recorded 
sites. Dispersion of repolarization depends on both activation time difference and APD 
difference. Since the activation time differences during pacing and during sinus rhythm are 
not the same, only the dispersion of APD was quantified to study the changes in the 
dispersion of repolarization.  
  Comparison was made between failing group and nonfailing group. Levels of significance 
were determined by the Student’s paired or unpaired t-test. Bonferroni adjustment was used 
to account for multiple comparisons. P<0.05 was considered statistically significant. Values 
were given as means ± S.D.    
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Figure 23. Representative RV free wall preparation and optical action potentials (AP).  (A) RV free wall 
preparation and mapping field of view (FOV). (B) Close-up view of two action potential recordings. (C) 
Representative optical action potentials from an evenly spaced array of locations spanning the whole FOV. 
Red and green dots in panel A and squares in panel C correspond to recordings in panel B. 
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5.4 Results 
5.4.1 Action Potentials in Failing Human RV 
Figure 24 shows AP recordings of five failing hearts (blue traces) and five nonfailing hearts 
(red traces) at the basic CL of 2000 ms. Three different columns of recordings are 
representative maximum APD, mean APD, and minimum APD, respectively. It can be seen 
that APD was longer in the failing group, especially for the maximum APD. The 
prolongation of APD could be associated with slower repolarization of APD (e.g., maximum 
APD of failing heart #1), or longer plateau of AP (e.g., maximum APD of failing heart #5). 
Furthermore, there existed heterogeneity of APD at the RV endocardium, as evident from 
the different duration of APs between the left column and the right column in Figure 24.  
 
Figure 24. Representative action potential (AP) recordings from individual failing (n=5, blue traces) and 
nonfailing (n=5, red traces)  human hearts at the pacing cycle length of 2000ms. On the left, the AP 
recordings with the maximum APD in the field of view (FOV). In the middle, the AP recordings with the 
mean APD in the FOV. On the right, the AP recordings with the minimum APD in the FOV. 
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Quantitative measurements of APD is shown in Figure 25. Figure 25-left shows APDs at 
multiple CLs for all 10 hearts. Blue and red curves correspond to five failing hearts and five 
nonfailing hearts respectively. The visual separation of the blue curves and red curves 
indicates that APDs of the failing group were different from and significantly longer than the 
nonfailing group. This difference was indeed statistically significant as shown in the Figure 
25-right. 
 
Figure 25. Individual APD restitution and summary APD restitution. On the left, APD at 80% 
repolarization (APD80) at various basic cycle lengths from 500ms to 2000ms from failing (blue lines) and 
nonfailing (red lines) human hearts. On the right, averaged APD80 of failing and nonfailing hearts, and P-
values for each comparison between failing and nonfailing groups. 
 
5.4.2 Dispersion of Repolarization 
One of the main goals of this study was to determine whether dispersion of APD was 
enhanced in the RV endocardium of failing human heart. We did observe dramatically 
increased dispersion of APD in the RV endocardium in three out of five failing hearts. 
Figure 26 shows one example from a failing heart (Fig. 26-top row) and one example from a 
nonfailing heart (Fig. 26-bottom row). Figure 26-left shows activation maps where we can 
see that the waves propagated from the bottom to the top of the field of view in both 
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examples. Figure 26-middle is the APD map, where APDs were color-coded within the same 
range of color map for both preparations. The APDs in the failing heart span from 420ms to 
640ms, the range of which is much larger than the range in the nonfailing heart (400ms to 
530ms). There was an apparent association between the APD heterogeneity and the 
structures of fiber bundles and trabeculae carneae at the RV endocardium, as shown in 
Figure 26-right.   
 
Figure 26. Representative examples of dispersion of repolarization at the endocardium of RV freewall from a 
failing heart and a nonfailing heart at the pacing cycle length of 2000ms. On the left, maps of activation 
(from blue to red) after a stimulus at the bottom of the field of view. In the middle, maps of APD80. It can 
be seen that the range of APD80 is much larger in the example of the failing heart (the top row) compared 
with that of the nonfailing heart (the bottom row). This indicates the dispersion of repolarization was 
enhanced in this failing heart. On the right, field of view with inverted color for better visualization of the 
structure.   
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    We quantified the dispersion of APD by measuring the difference between 95th and 5th 
percentiles of APD in the mapped area. Figure 27-left showed dispersion of APD in all 10 
hearts at multiple cycle lengths, with blue curves indicating failing hearts and red curves 
indicating nonfailing hearts. It can be seen that three blue curves corresponding to three 
failing hearts (#1, #2, #5) are separated from all the other curves, suggesting increased 
dispersion of APD in these three hearts. The increased dispersion of APD is due to 
heterogeneous prolongation of APD. The other two failing hearts did not have increased 
dispersion of APD, and their corresponding blue curves were clustered together with the 
nonfailing hearts (Figure 27-left). Due to the variations in different failing human hearts, the 
overall dispersion of APD in the failing group was not significantly different from the 
nonfailing group (Figure 27-right).  
 
Figure 27.Dispersion of repolarization quantified by APD80 at 95th percentile minus APD80 at 5th 
percentile. On the left, dispersion of repolarization at various basic cycle lengths from 500ms to 2000ms from 
failing (blue lines) and nonfailing (red lines) human hearts. On the right, averaged dispersion of 
repolarization within failing and nonfailing groups. It can be seen from the left panel that three failing hearts 
(#1, #2, #5) stand out from the other hearts by showing significant enhancement of dispersion of 
repolarization.  
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    Interestingly, APD alternans were induced by rapid pacing only in those three failing 
hearts with large APD dispersion (failing hearts #1, #2, #5), and occurred in regions with 
the maximum APD prolongation. The pacing rate at the onset of APD alternans was 164 ± 
12 bpm. These APD alternans could increase the dispersion of repolarization at fast heart 
rate, and provide the substrate for the initiation of arrhythmia, which was induced in failing 
heart #2 and #5. No alternans were observed in the other 2 failing and 5 non-failing hearts.   
5.4.3 Dynamics of Conduction Velocity 
The CV restitution for all individual hearts was shown in Figure 28-left. CV was significantly 
smaller in the failing group than the nonfailing group (Figure 28-right). In all the nonfailing 
hearts and three failing hearts, as we gradually decreased the pacing cycle length, the CV 
remained constant until the basic cycle length approached the refractory period. In contrast, 
the CV decreased progressively, starting at a much longer basic cycle length (1000ms) in two 
failing human hearts (failing hearts #2 and #5, Figure 28-left). As a result, the CV restitution 
for these two hearts had a much wider range of pacing CL with steep CV restitution than all 
the other curves. It was only in these two failing hearts that arrhythmia was induced. In 
addition, these two hearts were among the three hearts, which had enhanced dispersion of 
APD.    
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Figure 28. Conduction velocity (CV) restitution. On the left, individual CV restitution from failing (blue 
lines) and nonfailing (red lines) human hearts. On the right, averaged CV restitution. Since not every heart 
was paced faster than BCL of 500ms, CV was only averaged for BCL from 500ms to 2000ms. Note that 
the CV was significantly decreased in the failing hearts. Also note that CV restitutions in failing hearts #2 
and #5 have nonflat slope over a much wider range of basic cycle length.   
 
5.4.4 Induction of Arrhythmia by Rapid Pacing 
How the arrhythmia was initiated by rapid pacing in a failing human heart (#2) is illustrated 
in Figure 29, which shows the transition from paced beats to arrhythmia. Figure 29A shows 
the activation maps for beats 7, 8, 10, 11 and 12 and a dominant frequency map during the 
arrhythmia, which was initiated at beat 12. Figure 29B are the AP recordings from 4 different 
sites a, b, c and d, which are marked in the top-left activation map in Figure 29A. As 
described in the previous section, we observed in this heart APD alternans, which is evident 
from sites b, c and d. Dispersion of repolarization is increased due to dyssynchrony of APD 
alternans in different regions (i.e., no APD alternans in site a, 2:2 APD alternans in site b, 
and 3:3 APD alternans in sites c and d). The increased dispersion of repolarization due to 
alternans provided the substrate for arrhythmia. There were recurrent ectopic beats at site c 
(every three beats as marked by * in Figure 29B), which provided triggers for the induction 
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of arrhythmia. Arrhythmia was induced at beat 12 (marked by # in Figure 29B) due to an 
early arrival of an ectopic beats at site c.   
 
Figure 29. Arrhythmia induced by rapid pacing in failing heart #2. (A) The induction of arrhythmia is 
showed by sequential activation maps of beat 7 to beat 12. The dominant frequency map of the first 5 seconds 
of the arrhythmia is also shown. (B) Action potential recordings from four sites a, b, c and d. Asterisks (*) 
indicate activation were initiated by both the stimulus (square wave) at the bottom  and a foci at the site c 
(See beat 8 and 10 in panel A). Arrhythmia is induced by a early activation at site c at Beat 12(marked by 
#). Large dispersion of repolarization resulted from APD alternans, which are obvious in traces b, c and d. 
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5.5 Discussion 
In this study, we examined the remodeling and dispersion of repolarization in the RV 
endocardium using optical mapping of APs in a relatively large field of view. The major 
findings in this study include that (i) APD was significantly increased in the RV endocardium 
of the failing group compared to the nonfailing group, (ii) dispersion of APD was 
significantly enhanced in three out of five failing hearts, (iii) APD alternans was induced in 
those same three failing hearts with enhanced dispersion of APD, but not in the other two 
failing hearts, (iv) endocardial CV was significantly reduced in the failing group compared 
with the nonfailing group, and (v) ventricular arrhythmias were induced in failing hearts (#2 
and #5), which had enhanced dispersion of APD, APD alternans, and abnormal CV 
restitution. 
5.5.1 Prolongation of APD in Human Heart Failure 
APD prolongation has been consistently observed in various animal models of heart failure 
in both isolated cells and tissues, and has been reviewed previously (243). Compared with 
animal models of HF, human studies of APD remodeling in heart failure are rather limited 
and mostly in the isolated cells (19, 21, 131, 147) or isolated small-sized RV trabeculae (94, 
250), where spatial heterogeneity was not studied. We have recently explored transmural 
heterogeneity in the human LV wedge preparations and found that prolongation of APD 
was only observed at the epicardium but not the endocardium and midmyocardium (89). In 
contrast to the absence of APD prolongation in the LV endocardium (89), prolongation of 
APD was a consistent phenomenon in the RV endocardium in this study. It should be noted 
that this prolongation was heterogeneous in three failing hearts, leading to increased 
dispersion of APD. This spatial heterogeneity in APD prolongation suggests that the 
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location of tissue biopsy should be an independent variable in interpreting and comparing 
data from studies of isolated cells from the RV endocardium. It is likely that this spatial 
heterogeneity might also exist across RV epicardium, LV endocardium, and LV epicardium. 
This heterogeneity across the endocardium or epicardium has been implicated in several in 
vivo studies in patients and animal models of various heart diseases (26, 135, 179, 198, 248). 
  Based on previous studies of isolated human ventricular myocytes, the prolongation of 
APD could result from the down-regulation of transient outward K+ current (Ito) (19, 187, 
263), down-regulation of inward rectifier K+ current (IK1) (131), and slow delayed rectifier K
+ 
current (IKS) (256). Since most studies focused on the transmural heterogeneity, it remains to 
be determined why the prolongation of APD in the RV endocardium is spatially 
heterogeneous. Li et al. (147) provided some insights in a study of isolated cells from the RV 
epicardium from failing human heart. They showed that reduced Ito, IK1, and IKS in the cells 
from tissues with fibrosis and necrosis lead to significantly longer APDs in these cells than 
cells from tissues without histological abnormalities (147).  
  Prolonged duration increases the lability of AP, and could increase the susceptibility to 
secondary depolarization, such as early after-depolarization (EAD) or delayed after-
depolarization (DAD). No EAD was observed in failing hearts or nonfailing hearts in the 
present study. The only possible DAD observed in this study is the apparent ectopic beats 
during rapid pacing in one failing human heart, as shown in Figure 29. However, because the 
tissue is three dimensional, the apparent ectopic beats could also be explained as a 
breakthrough from a transmural conduction. The resistance to EAD and DAD even in the 
failing hearts is similar to the observation by Vermeulen et al. (250), who showed that when 
isolated RV trebeculae from failing human hearts was perfused with normal Tyrode's 
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solution, no DAD and EAD could be induced. They also showed that when the tissue was 
perfused with modified Tyrode's solution (mimic the extracellular milieu of patients with 
severe HF), DAD but not EAD was observed (250). The presence and underlying 
mechanism for DAD and EAD in HF patients remains to be determined in future studies.   
5.5.2 Dispersion of Repolarization in Human Heart Failure 
Increased QT dispersion in HF patients (9, 86, 209) suggested the existence of exaggerated 
dispersion of repolarization, which may predispose to ventricular arrhythmia (69, 93, 100, 
134, 248). While increased transmural repolarization heterogeneity was consistently not 
observed in the LV of failing human heart (89, 159), we demonstrated in this study that 
dispersion of APD could be enhanced in the RV endocardium (Figure 27-left) in three 
failing hearts. Increased dispersion of APD in these failing human hearts reflected the 
heterogeneous prolongation of APD, and could contribute to the increased dispersion of 
repolarization. It is true that the enhanced dispersion in the failing hearts was most 
significant at nonphysiologically slow rates, and approached the nonfailing hearts at more 
physiological rates. However, pauses after premature beats are common in HF patients and 
may produce significantly large dispersion at physiological heart rates (243). 
  The dispersion of repolarization could also be enhanced by the APD alternans. Pastore et 
al. (200) showed that spatially discordant APD alternans (i.e., out-of-phase APD alternans at 
different regions of the heart) resulted in a large dispersion of repolarization, which 
promoted initiation of arrhythmia.  The presence of discordant APD alternans preceding the 
induction of arrhythmia in Figure 29 supports the causal relationship between APD 
alternans and arrhythmia. It is intriguing that enhanced dispersion of APD and APD 
alternans occurred in the same failing hearts in this study. This association has been 
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implicated in an in vivo patient study by Chauhan et al. (38), who showed that dispersion of 
activation-recovery interval was higher in patients with T-wave alternans.   
5.5.3 Remodeling of Conduction Velocity and Arrhythmia 
We observed significantly decreased CV in the RV endocardium of the failing human heart. 
Since decreased cellular coupling occurs in the ischemic and hypertrophied human heart 
(202) and the failing human heart (89), this reduced cell-to-cell coupling might be 
responsible for the reduced CV in this study. Normal intercellular coupling allows 
electrotonic currents, which reduced the heterogeneity of APD between neighboring cells. 
The reduced coupling could decrease the electrotonic effects and increase the heterogeneity 
of repolarization. It could also promote the incidence of APD alternans (41).  
  Abnormal CV restitution has been shown to contribute to the susceptibility to arrhythmia 
(36, 216, 228). This correlation is consistent with our observation that arrhythmia was only 
induced when the CV restitution had a wide range of cycle length at which the restitution 
curve was steep (failing heart #2 an d #5 in Figure 28A). According to a computer 
simulation study by Qu et al. (216), in order to produce spatially discordant alternans and 
subsequent induction of arrhythmia, pacing rate needs to be fast enough to engage the steep 
portion of CV restitution. A wider steep portion of CV restitution allows this engagement to 
occur at a slower pacing rate and therefore increases the likelihood of arrhythmia. This 
abnormal CV restitution has been previously reported in the failing human hearts by Kawara 
et al. (123), and was found to be closely associated with stringy and patchy fibrosis (123). 
Derksen et al. (59) further showed that delayed inactivation of depolarizing currents at tissue 
discontinuities contributed to the abnormal CV restitution.  
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5.5.4 Variability in Human Heart Failure 
In this study, while the RV endocardium from failing hearts shared similar functional 
remodeling (e.g., prolongation of APD), there clearly was significant variability. We did not 
observe increased dispersion of repolarization, alternans, and abnormal CV in two out of 
five failing hearts. Even the consistently observed prolongation of APD appears to have 
different mechanisms in different hearts (Figure 24), because the prolongation was due to a 
slow repolarization phase (phase 3) in one failing heart (#1), while it was due to a longer 
plateau (phase 2) in other failing hearts. Nevertheless, there was a close correlation between 
the functional remodeling (in repolarization and conduction) and the susceptibility to 
arrhythmia. Advancing the understanding of the arrhythmic mechanisms could facilitate the 
development of strategies to identify the HF patients who are more likely to benefit from 
anti-arrhythmic therapies, such as implantable cardioverter defibrillator (ICD).  
5.6 Limitation 
There are limitations in this study. First, the etiology of HF, its duration, and medical 
treatment are varied and uncontrolled, and we did not have access to clinical data due to de-
identified tissue protocol. Therefore, only remodeling common to all the failing human 
hearts can be revealed in the study. Second, we did not study other pacing protocols, such as 
S1-S2-S3 protocol and short-long-short sequence of pacing, which have been shown to 
enhance the dispersion of repolarization (69, 93). Third, the isolated tissue preparations were 
mechanically unloaded due to the surgical opening of the tissue and the application of 
excitation-contraction uncoupler. It remains to be determined how the mechanical loading 
affects the electrical property in the human heart. Fourth, in isolated denervated preparations 
we did not use sympathetic stimulation and could not study the effects of heterogeneity of 
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innervation, which was shown to affect the dispersion of repolarization (168). Fifth, we did 
not quantify the local gradient of APD, which was a more sensitive marker for arrhythmia 
vulnerability than global dispersion of repolarization. We chose not to quantify it because 
there were many boundaries of fiber bundles and trabeculae carneae, the gradient across 
which was not an accurate representation of the true gradient in the same layers of 
myocardium. Finally, the failing human hearts in this study were all in the end stage of HF. 
These results might not apply to the failing human heart in earlier stages of HF.  
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6. Remodeling of Calcium Handling in Human 
Heart Failure 
6.1 Abstract 
Heart failure (HF) is an increasing public health problem accompanied by the rapidly aging 
global population. Despite considerable progress in managing the disease, the development 
of new therapies for effective treatment of HF remains a challenge. To identify targets for 
early diagnosis and therapeutic intervention, it is essential to understand the molecular and 
cellular basis of calcium handling and the signaling pathways governing the functional 
remodeling associated with HF in humans. Calcium cycling is essential mediator of cardiac 
contractile function. Thus, remodeling of calcium handling is thought to be one of the major 
factors contributing to the mechanical and electrical dysfunction in HF. Active research in 
this field aims to bridge the gap between basic research and effective clinical treatment of 
HF. This chapter reviews the most clinically relevant human studies regarding the 
remodeling of calcium handling. We also discuss their connections to the current and 
emerging clinical therapies for HF patients.  
6.2 Introduction 
Heart failure (HF) is a rising public health problem, with a prevalence of over 5.8 million in 
the USA, over 23 million worldwide, and continue to increase (33, 157). The contractile 
dysfunction and arrhythmogenesis associated with HF is closely related to the remodeling of 
calcium handling (18), which, in turn, is partially controlled by several signaling pathways in 
which Ca2+ has a prominent role (15). Deriving a mechanistic understanding of alterations in 
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calcium handling and calcium signaling is a critical step towards the development and 
improvement of physiology-based treatments for HF. 
6.3 Overview of Cardiac Calcium Signaling 
Ca2+ plays a central part in regulating excitation-contraction (EC) coupling and in modulating 
systolic and diastolic function in the heart as shown in Figure 30. Ca2+ signal transduction in 
the EC coupling comprises four steps (15, 107, 180). Firstly, the trigger Ca2+ current (ICa) is 
generated by the L-type Ca2+ channels expressed in the transverse tubules (T-tubules) 
following membrane depolarization. Secondly, the Ca2+ ions diffuse across the narrow 
junctional zone to activate ryanodine receptors (RyRs) and generate Ca2+ sparks, which is a 
considerable amplification of the original trigger Ca2+ signal. This process is known as Ca2+-
induced Ca2+ release (CICR). Thirdly, the Ca2+ influx from the sarcoplasmic reticulum (SR) 
then diffuses out to activate contraction following Ca2+ binding to troponin-C. Lastly, Ca2+ is 
transported back to SR by SR Ca2+-ATPases (SERCA) and out of cell via Na+/Ca2+ 
exchanger (NCX). Abnormal handling of intracellular Ca2+ at any of these steps can cause 
cardiac dysfunction in HF (122).  
    Intracellular Ca2+ homeostasis of cardiac myocytes is regulated by the phosphorylation of 
several key Ca2+-handling proteins. One important regulatory kinase is cAMP-dependant 
protein kinase (PKA), which has been shown to regulate L-type Ca2+ channels, RyR and 
phospholamban (PLN). Despite the fact that global PKA activity is not changed in the 
failing human heart (24, 127), its local activity in the RyR macromolecular signaling complex 
might be locally increased (144, 169).  
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Figure 30. Intracellular Ca2+ cycling and regulation by signaling pathways. After the activation of 
sarcolemma (including T-tubules), Ca2+ enters cytoplasm through L-type Ca2+ channel. The entered Ca2+ 
then induces a much larger Ca2+ release from the sarcoplasmic reticulum (SR) via the ryanodine receptor 
(RyR). The released Ca2+ binds with Troponin C to activate contraction. The relaxation starts when Ca2+ is 
returned by sarcoplasmic reticulum Ca2+ ATPase (SERCA) back to SR and via Na+/Ca2+ exchanger 
(NCX) outside of the cell. Some Ca2+ enters mitochondria to stimulate the production of ATP which is 
utilized for contraction and transcription. SERCA is inhibited by the dephosphorylated phospholamban 
(PLN). PLN can be phosphorylated by protein kinase A (PKA) and Ca2+/calmodulin-dependent kinase 
(CAMKII), both of which can be activated by β-adrenergic stimulation. PLN can be dephosphorylated by 
protein phosphotase 1 (PP1), which can be activated through Gαq-coupled receptor (angiotensin II receptor, 
endothelin 1 receptor, or α-adrenergic receptor). A portion of Ca2+ enters into mitochondria to stimulate the 
production of ATP, which is used for contraction and transcription. α, G-protein subunit α; β, G-protein 
subunit β; γ, G-protein subunit γ; AC, adenylyl cyclase; cAMP, cyclic adenosine monophosphate. 
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    Another important regulatory kinase is the Ca2+/calmodulin-dependent protein kinase II 
(CaMKII).(166) CAMKII is a protein kinase that modulates several intracellular Ca2+-
handling proteins such as RyR, PLN, L-type Ca2+ channels as well as Na+ channels (166). 
CAMKII is associated directly with the RyR and modulates the activity of RyR (48, 98, 260). 
Phosphorylation of PLN via CAMKII or PKA enhances the SR Ca2+ uptake via increased 
SERCA activity. Activity of CAMKII was shown to be significantly increased in the failing 
human heart and is correlated with the impaired ejection fraction (127, 239). Both PKA and 
CAMKII can be activated by β-adrenergic stimulation. 
    Finally, multiple isoforms of protein kinase C (PKC) might also play a role in regulating 
the Ca2+ handling. PKCα is the dominant isoform of PKC in the human heart (99) and is 
triggered by the activation of Gαq coupled receptors (angiotensin II receptor, endothelin-1 
receptor, and the α-adrenergic receptor) (268). PKCα could phosphorylate protein 
phosphatase inhibitor 1 (I-1), consequently increasing the activity of protein phosphotase 1 
(PP1), and then leading to enhanced phosphorylation of PLN and thus decreasing the 
activity of SERCA (32). The level of PKC is increased in human HF (27, 233, 252). The role 
of other isoforms of PKC in regulating calcium handling remains to be elucidated.  
6.4 Alteration in intracellular Ca2+ and Mechanical 
Dysfunction in Failing Human Heart 
The amount of Ca2+ delivered to the cytoplasm and the rate of Ca2+ removal from the 
cytoplasm are the two of the major factors determining the rate, intensity and duration of the 
contraction (269). Understanding of alterations in the intracellular Ca2+ concentration ([Ca2+]i) 
and their causal role in contractile dysfunction in the failing human heart has been greatly 
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advanced by the use of fluorescent [Ca2+]i indicators (20, 21, 94, 96, 97, 160, 180, 204, 206, 
245), which reflect changes in the free [Ca2+]i necessary for the activation of contractile 
proteins (4, 23). 
    In isolated cells and tissues from failing human hearts, decreased amplitude of Ca2+ 
transient measured by the fluorescent intracellular Ca2+ indicators implies reduced Ca2+ 
release from SR (21, 133, 204). This is correlated with decreased peak stretch amplitude, a 
measure of myocardial contraction (105, 107). The reduced amplitude of Ca2+ transient is 
associated with decreased EC coupling gain (92) and decreased SR Ca2+ content (60, 112, 
154, 204, 207, 208). 
    Moreover, the Ca2+ transient from failing human heart exhibits a reduced rate of Ca2+ 
removal (21, 94, 204). The slower rate of recovery of Ca2+ transient recovery is associated 
with a marked delay in tension relaxation in the failing human heart (94). Finally, failing 
human heart exhibits increased the resting intracellular Ca2+ level, leading to diastolic 
dysfunction (21, 97).  
    Altered [Ca2+]i is frequency-dependent and most obvious at high heart rate (106). 
Normally, the amplitude of [Ca2+]i transient is larger at higher stimulation frequencies (4). In 
human HF, however, the amplitude of Ca2+ transient was decreased at faster stimulation 
rates, leading to a reduced tension development at higher frequencies (97, 206). Increased 
resting [Ca2+]i and a fusion of Ca
2+ transient at fast frequencies may also occur, leading to an 
increase of end-diastolic tension and a decrease of active tension generation associated with 
incomplete relaxation and twitch fusion (97). The blunted or negative force frequency 
relationship (FFR) observed in both in vivo and in vitro studies in failing human hearts is in 
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contrast with the positive FFR in nonfailing human hearts (79, 97, 108, 184), and is 
associated with altered Ca2+ and Na+ homeostasis as well as an inability to increase the SR 
Ca2+ content at increasing stimulation frequencies (207, 208).  
    The alteration of Ca2+ transient in failing human hearts is also region-dependent. We 
recently demonstrated the transmural heterogeneous remodeling of Ca2+ handing in the 
coronary-perfused left ventricular wedge preparations from failing and nonfailing human 
hearts (160). The sequence of Ca2+ transient relaxation is from epicardium to endocardium in 
both failing and nonfailing human heart at a slow heart rate (e.g., 0.67Hz/40 BPM) during 
endocardial pacing, because the difference of Ca2+ transient duration between 
subendocardium and subepicardium (or duration difference) is larger than the conduction 
time from subendocardium to subepicardium (Figure 31). Interestingly, this sequence is 
reversed at a fast heart rate (e.g., 1.67Hz/100 BPM) in the failing human heart due to a 
significant decrease of this duration difference (Figure 2C&D). In contrast, this sequence is 
not reversed in the nonfailing human heart because the duration difference is not 
significantly changed at faster frequencies (Figure 2B&D). We hypothesize that this reversed 
sequence of relaxation at fast heart rates could contribute to the end-systolic dysfunction (79) 
in the failing human heart. The maintenance of the normal relaxation sequence at slow heart 
rates in the failing hearts provides another mechanism for the beneficial effects of the heart-
rate reduction in the patients with HF (241).  
6.5 Molecular and Cellular Basis of Abnormal Calcium 
Handling and Signaling in Human HF 
Alteration in the [Ca2+]i is attributed to the abnormal calcium handling in the EC coupling 
process, which is operated by sarcolemma and SR, including L-type Ca2+ channels, RyR, 
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NCX, SERCA2a, etc. Changes of EC coupling in HF have been reviewed in detail elsewhere 
(18, 106, 268). Here we mainly focus on reviewing the results regarding the failing human 
heart.  
 
Figure 31. Region-dependent and cycle-length-dependent calcium transient duration (CaTD) in failing 
human heart. (A) CaTD was quantified at 80% relaxation (CaTD80). (B) CaTD80 at nonfailing 
human hearts (n=6) at subendocardium (sub-ENDO), midmyocardium (MID), and subepicardium (sub-
EPI). (C) CaTD80 at failing human hearts (n=5). (D) The difference of CaTD80 between sub-ENDO 
and sub-EPI. It can be seen that this difference is significantly reduced in failing heart at faster heart rate 
(cycle length at 600ms).(160) These data are obtained from Ca2+ transient measured using Rhod-2AM 
from the coronary-perfused wedge preparations from both failing and nonfailing human hearts. 
 
6.5.1 Calcium-Induced Calcium Release (CICR)  
Triggering of CICR (i.e., ICa) in the failing human heart is mostly unchanged (20, 21, 172, 
204), though inhibition of ICa was observed at higher frequencies (234). Thus, the smaller 
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Ca2+ transient observed in HF is mainly due to a reduced capability of ICa to trigger Ca
2+ 
release from the SR (or a reduced EC coupling gain).  
    The reduced EC coupling gain may result from the hyperphosphorylation of RyRs in the 
failing human heart (169). PKA hyperphosphorylation of RyRs leads to the dissociation of 
the FKBP12.6 regulatory subunit, which inhibits the coupled gating of arrays of RyR 
channels and thus could result in a loss of EC coupling gain (169). This is supported by the 
reduced amplitude and changed properties of Ca2+ sparks measured from isolated ventricular 
myocytes from failing human hearts (153). More discussion of RyRs can be found in the 
section 6.5.2. 
    Rapid activation of RyRs by the ICa is facilitated by the close proximity of the L-type Ca
2+ 
channels and RyRs. Reduced EC coupling gain in HF could thus also originate from the 
geometric disarrangement of RyRs and L-type Ca2+ channels, as suggested by the 
spontaneous hypertensive rat with HF (SHR-HF) (92). Disorganization of T-tubules and a 
decrease in the colocalization of L-type Ca2+ channels and RyRs have been demonstrated in 
the fixed ventricular samples from failing human hearts (47). The actual loss of T-tubules in 
isolated myocytes from failing human heart was reported in one study (164) but not in 
another (197), findings that might be explained by the large spatial variations in T-tubule 
remodeling in human HF (47).  
    The unltrastructural defects in the T-tubule system were demonstrated to cause the 
dyssynchronous Ca2+ release (or defective EC coupling) by confocal line scanning techniques 
in the isolated ventricular myocytes from SHR-HF, with Ca2+ release being delayed in certain 
regions of a myocyte compared to the other normally coupled areas (237). Louch et al. 
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showed modest dyssynchrony of Ca2+ release in the isolated myocytes from failing human 
hearts (163). While the local delayed SR Ca2+ release was confirmed in the whole heart level 
in SHR-HF (255), no study has been done so far to demonstrate the dyssynchronous Ca2+ 
release in tissue levels from the failing human heart. However, the morphological changes of 
Ca2+ transient observed in our recent left ventricular wedge preparations from failing human 
hearts imply the potentially important role of dyssynchronous Ca2+ (160). We observed two 
components in the rising portion of Ca2+ transient, with a slow rising component following 
an initial fast rising component (Figure 32A&B) (160). It is possible that the first fast-rising 
component corresponds to the normally triggered Ca2+ release and the second slow-rising 
component corresponds to the delayed Ca2+ release, which has been showed in SHR-HF 
(255). Interestingly, this morphological change of Ca2+ was only observed at the 
subendocardium in 60% of the studied failing human hearts (160). This regional difference 
might result from higher susceptibility to ischemia of endocardium compared with 
epicardium (81, 117), and suggests that the extrapolation of results from one region (e.g., 
epicardium) to another region (e.g., epicardium) in human studies should be done with 
caution. This delayed Ca2+ release might be also underlie the slower recovery of intracellular 
Ca2+ relative to the recovery of the action potential observed in our study (Figure 3A&C).  
That is, the Ca2+ transient outlasts the action potential at the subendocardium of the failing 
human heart, which might lead to phase-3 early afterdepolarization (34).   
    The reduced EC coupling gain could also result from decreased SR Ca2+ content, which 
has been extensively demonstrated in human HF (60, 154, 204, 207, 208). The success of 
molecular therapies aimed at restoring SR Ca2+ content further underscores the importance 
of SR Ca2+ content (118, 236). Reduced SR Ca2+ content in the failing human heart could 
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result from leaky RyRs, reduced SR Ca2+ uptake via SERCA2a, and increased Ca2+ 
extrusion via NCX, which are reviewed in the sections below (6.5.2-6.5.3).  
 
Figure 32. Morphological changes of calcium transient (CaT) and its relation to action potential (AP). (A) 
Simultaneous recordings of AP and CaT at one site at subendocardium from a failing human heart (F, top) 
and a nonfailing human heart (NF, bottom). (B) The two CaTs from panel A are overlapped for easy 
comparison. Compared to the CaT from NF, there is a distinct second rising component (labeled by “II”) in 
the CaT from failing human heart. Note that this second component was only observed at the sub-
endocardium in 60% of the studied failing human hearts. (C) CaT duration at 80% relaxation (CaTD80) 
minus AP duration at 80% (APD80). It can be seen that this duration difference is significantly longer at 
the subendocardium in the failing human heart compared with nonfailing human heart, which is reflected in 
the example shown in panel A.(160) 
 
6.5.2 RyR 
Most studies showed no change in the protein expression of RyR in human HF (18, 106). 
However, the characteristics of Ca2+ sparks are altered in isolated myocytes from failing 
human hearts (153). Furthermore, RyRs in human HF are ―leaky‖ (169), contributing to the 
reduction of SR Ca2+ content (132). The SR Ca2+ leak occurs in despite of the reduced SR 
Ca2+ loading in a canine model of HF (132).  
    Leaky RyR is thought to result from hyperphosphorylation of RyR by PKA or CAMKII. 
Increased Ca2+ sensitivity and open probability of RyR in failing human heart was first 
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observed by Marx et al. (169) They concluded that the increased local PKA-phosphorylation 
of RyR in HF lead to the disassociation of FKBP12.6 from RyRs, leading to higher open 
probability at rest (169). They also observed decreased association of phosphatases (PP1, 
protein phosphotase 2A [PP2A]) to RyR, which may exacerbate PKA-hyperphosporylation 
of RyR (169). The PKA-hyperphosphoryation of RyRs could also result from the deficiency 
of phosphodiesterase 4D (PDE4D), which resides in the RyR macromolecular signaling 
complex and regulates the local concentration of cAMP that activate PKA (144). The 
capability of PKA phosphorylation in reducing the RyR/FKBP12.6 association remains 
controversial because it was not confirmed by some groups (119, 150). 
    Increased SR Ca2+ leak in isolated myocytes from failing rabbit heart was shown to relate 
to the hyperphosphoryation of RyR by CAMKII (1). The Ca2+ leak was reduced by the 
inhibition of CAMKII but not altered by PKA inhibition (1), suggesting the potential role of 
CAMKII inhibition in improving the Ca2+ handling in HF. This hypothesis is further 
supported by a recent study by Sossalla et al. (239), who showed a significant increase in the 
expression the CAMKII in both left and right ventricles of the failing human heart , and that 
the inhibition of CAMKII reduced the SR Ca2+ leak and increased the Ca2+ content. 
Importantly, they also showed that inhibition of CAMKII improved contractility in isolated 
ventricular trabeculae.(239) They reported that CAMKII inhibition restored the positive 
FFR.(239) This is in sharp contrast to the study by Kushiner et al. (136), which showed that 
CAMKII inhibition completely abolished the positive FFR in mouse heart. The result from 
Kushiner et al.'s study is consistent with the hypothesis that CAMKII is responsible for 
sensing the frequency of Ca2+ oscillation (54) as well as for causing the positive FFR via the 
increase of phosphorylation of RyR and PLN at increasing frequencies (260, 271). Kushiner 
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et al. also showed that RyR phosphorylation by CAMKII was decreased in failing human 
heart in despite of the global increase of CAMKII (136), and suggested that the impaired 
RyR phosphorylation by CAMKII plays a role in blunted FFR in human HF. Further studies 
are needed to resolve the areas of controversy and clarify the molecular mechanism and the 
promise of CAMKII inhibition in improving the Ca2+ handling in human HF.  
    While much evidence supports altered regulation and function of the RyR leading to 
abnormal Ca2+ handling in failing human heart, there are studies indicating the opposite. 
Recordings of currents through the RyR from failing human hearts did not reveal any 
significant alterations at a single channel level (113). Jiang et al. observed neither structural 
nor functional change of RyRs from the failing human heart but did report a significant 
reduction in SERCA2a expression, suggesting that abnormal Ca2+ uptake may contribute 
more to the altered Ca2+ handling in human HF (119).  
6.5.3 SERCA2a, PLN and NCX 
SR Ca2+ uptake was reduced in the failing human heart (57, 108, 204, 230). This might be 
due to depressed protein expression of SERCA2a. Hasenfuss et al. observed downregulation 
of SERCA2a expression as well as a significant correlation between SERCA protein levels 
and SR Ca2+ uptake in failing human hearts (108). Overexpression of SERCA2a has shown 
to restore the Ca2+ handling and the contractile function with positive FFR in isolated failing 
human myocytes (56, 57). While some studies observed the downregulation of protein 
expression of SERCA2a in the failing human heart, others did not find any change in the 
protein expression of SERCA2a (85). This inconsistency might be explained by our recent 
findings (160). We observed down-regulation of SERCA2a expression in samples from the 
subendocardium of failing human hearts with ischemic cardiomyopathy but not in samples 
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from epicardium or from failing hearts with dilated cardiomyopathy, suggesting that the 
alteration of SERCA2a expression might be region-dependent as well as the HF etiology-
dependent (160).  
    Besides the potential decrease in protein expression, the decreased activity of SERCA2a in 
HF might also result from altered regulation. This is supported by the findings that 
decreased SR Ca2+ uptake was observed in despite of unchanged protein levels of SERCA2a 
(57, 230, 231). 
    SERCA2a is directly regulated by PLN which is mainly phosphorylated by PKA and 
CAMKII (85). PLN inhibits SERCA2a activity when it is not phosphorylated, while its 
phosphorylated form disassociate from SERCA2a. In the failing human heart, majority of 
the studies indicate no change in the protein expression of PLN (85, 160), which is 
consistent with our recent study (160), However, phosphorylation state of PLN was 
decreased in the failing human heart (49, 57, 231), suggesting increased inhibition of 
SERCA2a by PLN in the failing human heart. PLN is mainly phosphorylated by PKA at 
serin-16 and by CAMKII at threonine-17. Phosphorylation at threonine-17 is decreased due 
to increased dephosphorylation by calcineurin in the failing human heart with dilated 
cardiomyopathy (186). PLN phosphorylation at serin-16 is decreased presumably due to 
increased level of PP1 in the failing human heart (177, 231), which might be due to an 
increased level of PKCα (27, 32). Interventions to attenuate the inhibitory effect of PLN on 
SERCA2a have been tested in animal models. Minamisawa et al. found that knockout of 
PLN significantly increased SR Ca2+ content and completely rescued the spectrum of heart-
failure phenotype in a mouse model of HF (174). Decreased PLN expression via adenoviral 
gene transfer of antisense of PLN was shown to improve both contraction and relaxation in 
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isolated myocytes from failing human hearts (56). Inhibition of PKCα was shown to increase 
the SR Ca2+ load and protect the mouse from HF (32, 156). The importance of PKCα and 
other isoforms of PKC in the Ca2+ handling in human HF remains to be determined.  
    While protein expression of NCX was found upregulated in most animal models of HF 
(18), it is less consistent in the failing human heart with either increased or unchanged 
protein expression of NCX (106). In contrast to reduced SR Ca2+ uptake, the NCX current 
density as a function of [Ca2+] was not changed in the failing human heart (204). However, 
the contribution of NCX to the [Ca2+]i relaxation was increased due to the depressed SR 
Ca2+ uptake (204). Furthermore, the preference of NCX current direction during the action 
potential plateau shifted from inward direction (Ca2+ efflux) to outward direction (Ca2+ influx) 
due to a reduced submembrane [Ca2+]i and increased [Na
+]i in the failing human heart (259). 
The reversed-mode NCX during AP plateau could contribute to a slow decay of [Ca2+]i 
transient (60, 259), which may facilitate contraction at slow heart rates but may also lead to 
diastolic dysfunction at faster heart rates (208).  
6.5.4 Loss of metabolic capacity 
Ca2+ handling and energy homeostasis are interdependent (249). Ca2+ homeostasis relies on 
efficient energy-driven ionic fluxes, i.e., through SERCA2a and Na+-K+ ATPase, while 
[Ca2+]i in turn determines energy consumption through contraction and Ca
2+ transport as 
well as energy production via the regulation of ATP generation in mitochondria (16, 249). 
Disturbance of the finely tuned balance between the two could be responsible for abnormal 
Ca2+ handling and diminished contractility that are hallmarks of HF.  
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    HF is associated with defects in energy metabolism, with decreased energy production as 
well as impaired energy transfer and utilization (249). These impaired cardiac energetics may 
represent the thermodynamic limit for Ca2+ handling (55). Reduced local ATP/ADP ratio, 
due to a local lack of creatinine kinase, could affect the kinetic and thermodynamic efficiency 
of SERCA in HF (55), providing another mechanism for impaired SR Ca2+ uptake. Indeed, 
ATP was reported to protect SERCA2a from being denatured by hydroxyl radicals (267), 
implying that energy starvation might render SERCA2a unprotected from increased 
oxidative stress in human HF.  
    Improving the myocardial energetics has been shown to normalize the Ca2+ cycling in 
isolated failing human myocytes (103). β-blockers, which decrease the energy demand and 
thus ameliorate the mismatch between energy production and consumption, has been shown 
to normalize the function and regulation of key Ca2+ handling proteins in failing human 
hearts (220). Similarly, left ventricular assist devices (LVADs), which unload the heart and 
support the circulation, impart improved Ca2+ handling in human HF (37, 169). Finally, 
hemodynamic improvement by cardiac resynchronization therapy (CRT) is correlated with 
improved Ca2+ handling in the subset of HF patients who respond to this therapy (247). On 
the other hand, restoration of Ca2+ homeostasis may result in improved cardiac energetics 
(58).  
6.6 Conclusion 
It has been well recognized that abnormal Ca2+ handling is the key pathophysiological 
mechanism in human HF. On the other hand, the understanding of the underlying molecular 
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and cellular mechanisms for the altered calcium handling in the failing human heart remains 
incomplete.  
    The is partly due to the complexity of system, which involves the interplay between a 
number of signaling pathways that regulates the Ca2+ homeostasis at different time scales 
(114, 236). That is, while interrupting or augmenting one of pathways in the cascade might 
lead to expected beneficial therapeutic effects; it might also produce unexpected deleterious 
effects (236). Nevertheless, the structure of this complex system are continuingly being 
revealed by ongoing basic and clinical researches, which carry the hope of facilitating the 
development of effective diagnosis and treatment of HF. The progress is also slowed by 
limited data from human studies. While many mechanistic hypothesis and potential 
therapeutic intervention for the abnormal Ca2+ handling in HF are being proposed and 
tested in the animal models of HF, the examination of these hypothesis and therapies using 
functional studies of isolated cells or tissues from the failing human heart are rather limited. 
We believe that the basic understanding and clinical translation can be greatly facilitated by 
testing the hypothesis in the explanted human heart donated for research by patients and 
donors (67).  
    Gaining a clearer understanding of the causative mechanisms of abnormal Ca2+ handling 
is crucial to developing promising new therapies to treat HF. Despite our best efforts, there 
are currently only two major medical pharmacological approaches available to the clinician 
for the treatment of patients with HF: blockade of the -adrenoreceptor and inhibition of 
the RAA axis. These first line agents are used to treat non-ischemic (the majority of which 
are idiopathic), ischemic and valvular cardiomyopathies, even though we recognize 
fundamental differences in the insults that cause these separate conditions. Such blanket 
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approaches demonstrate the limits of our current knowledge, and the need for further 
observation and testing before new therapies can be delivered to the patient. Moreover, it is 
clear that many pathways involving Ca2+ handling converge on and act through a few key 
molecules. Thus, the complex biological processes leading to HF must be further dissected 
with respect to specific isoforms, subcellular locations and etiology of HF. Similarly, it is 
important to realize that individual drugs effects must be categorized based on the species 
and type of animal model used. Finally, we must recognize that the road to developing a 
human therapeutic agent, i.e., going from the bench to the bedside, is a time consuming and 
expensive one, and littered with failures. These complexities may explain why after years of 
research, the clinical armamentarium for reversing HF remains rather limited. Despite these 
drawbacks, it is encouraging that many promising new therapies to ameliorate abnormal 
calcium handling are visible on the horizon, based on findings in animal models of HF. 
Increased research on functional human heart tissue would facilitate translation of these 
findings to clinic.   
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7. Transmural Heterogeneity and Remodeling of 
Ventricular Excitation-Contraction Coupling in 
Human Heart Failure 
7.1 Abstract  
Excitation-contraction (EC) coupling is altered in the end-stage heart failure (HF). However, 
spatial heterogeneity of this remodeling has not been established at the tissue level in failing 
human heart. The objective is to study functional remodeling of EC coupling and calcium 
handling in failing and nonfailing human hearts.  
    We simultaneously optically mapped action potentials (AP) and calcium transients (CaT) 
in coronary-perfused left ventricular wedge preparations from nonfailing (n = 6) and failing 
(n = 5) human hearts. Our major findings are: (1) CaT duration minus AP duration was 
longer at sub-endocardium in failing compared to nonfailing hearts during bradycardia (40 
beats/min). (2) The transmural gradient of CaT duration was significantly smaller in failing 
hearts compared with nonfailing hearts at fast pacing rates (100 beats/min). (3) CaT in 
failing hearts had a flattened plateau at the midmyocardium; and exhibited a ―two-
component‖ slow rise at sub-endocardium in three failing hearts. (4) CaT relaxation was 
slower at sub-endocardium than that at sub-epicardium in both groups. Protein expression 
of sarcoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) was lower at sub-endocardium than 
that at sub-epicardium in both nonfailing and failing hearts. SERCA2a protein expression at 
sub-endocardium was lower in hearts with ischemic cardiomyopathy compared with 
nonischemic cardiomyopathy.  
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    In conclusion, for the first time, we present direct experimental evidence of transmural 
heterogeneity of EC coupling and calcium handling in human hearts. End-stage HF is 
associated with the heterogeneous remodeling of EC coupling and calcium handling.  
7.2 Introduction 
Congestive heart failure (HF) is one of the leading causes of death in Western countries (7). 
Depressed contractility during congestive HF is associated with altered excitation-
contraction (EC) coupling, in general, and calcium handling, in particular (14, 17, 203, 235).  
    Most experimental studies of EC coupling in human hearts were conducted in isolated 
cells or muscle strips (21, 95, 104, 107, 181, 182, 205, 246), where anatomical differences 
could not be investigated. However, the anatomical location of the region from which cells 
are harvested could be very important (235). Animal studies suggest that transmural 
heterogeneities of EC coupling and intracellular calcium exist. For example, Cordeiro et al. 
observed that the latency to onset of contraction was shorter, and SR Ca2+ content is larger 
in epicardial cells as compared to endocardial cells in normal canine left ventricle (45). 
Investigating calcium handling, Laurita et al. showed that the recovery of intracellular 
calcium in canine left ventricle was slower in cells near the endocardium (ENDO) compared 
with cells near the epicardium (EPI) (140). We have recently described spatial heterogeneity 
of action potential (AP) in human ventricle and its implication for the vulnerability to 
arrhythmias (90). However, spatial heterogeneity of EC coupling and intracellular calcium 
handling in human heart remains unclear.  
    It was suggested by a molecular study by Prestle et al. that the transmural heterogeneity of 
calcium handling was enhanced in the failing human hearts compared with nonfailing human 
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hearts (211). In failing human hearts, the protein expression of the sarcoplasmic reticulum 
Ca2+-ATPase 2a (SERCA2a) was reduced significantly in the sub-ENDO compared to the 
sub-EPI,(211) which might lead to the heterogeneous uptake of intracellular calcium and 
facilitate the induction of ventricular arrhythmias (140, 141, 264). In spite of the molecular 
evidence, it remains unknown if the heterogeneity of EC coupling and calcium handling is 
present and how it is functionally remodeled in heart failure. Furthermore, it is unknown if 
this remodeling could contribute to the increased ventricular arrhythmogenesis and 
mechanical dysfunction associated with human HF.  We hypothesize that across the intact 
transmural wall there exists intrinsic heterogeneities of EC coupling and calcium handling 
and thus the susceptibility to remodeling during HF differs in different transmural layers of 
the left ventricle. To test this hypothesis, dual optical mappings of AP and calcium transient 
(CaT) were conducted in left ventricular (LV) wedge preparations from both failing and 
nonfailing human hearts.  
7.3 Methods 
7.3.1 Experimental Protocol 
The study was approved by the Washington University Institutional Review Board. Both 
failing (n = 5) and nonfailing (n = 6) human hearts were optically mapped in this study. For 
Western blot assay, we used tissue from 19 hearts. Patient information is shown in Table 2. 
    The isolated LV wedge preparation has been described in our previous paper (90). Briefly, 
a piece of LV wedge from the scar-free post-lateral LV free wall perfused by the left 
marginal artery (Figure 33A) was isolated and cannulated. Tissue was immobilized by 
blebbistatin (10~20 µM, Tocris Bioscience, Ellisville, MO) to suppress motion artifacts in  
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Table 2.  
Patient Information     
# Group Gender Age Diagnosis Experiment 
1 Nonfailing Male 55 Death from stroke Mapping, WB 
2 Nonfailing Female 59 Anoxic brain injury  post cardiac arrest Mapping, WB 
3 Nonfailing Male 53 Intracranial hematoma Mapping, WB 
4 Nonfailing Male 56 Intracranial hematoma Mapping, WB 
5 Nonfailing Female 47 Brain death due to anoxia Mapping, WB 
6 Failing Female 65 Ischemic cardiomyopathy Mapping, WB 
7 Failing Male 63 Ischemic cardiomyopathy Mapping, WB 
8 Failing Male 49 Idiopathic cardiomyopathy Mapping, WB 
9 Failing Female 54 Idiopathic cardiomyopathy Mapping, WB 
10 Failing Female 54 Idiopathic cardiomyopathy Mapping, WB 
11 Nonfailing Female 50 Brain death from anoxia Mapping 
12 Nonfailing Female 66 Brain Death from hemorrhaging WB 
13 Failing Male 61 Ischemic cardiomyopathy WB 
14 Failing Male 64 Ischemic cardiomyopathy WB 
15 Failing Female 49 Ischemic cardiomyopathy WB 
16 Failing Male 50 Ischemic cardiomyopathy WB 
17 Failing Male 47 Idiopathic dilated cardiomyopathy WB 
18 Failing Female 44 Idiopathic cardiomyopathy WB 
19 Failing Male 70 Idiopathic dilated cardiomyopathy WB 
Mapping indicates optical mapping experiments  
WB, Western blotting assay 
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optical recordings (77). The tissue was co-stained with RH237 and Rhod-2 AM for 
simultaneous mapping of AP and CaT. Representative recordings of voltage and calcium 
collected at different layers of the LV wedge are shown in Figure 33C. The definition of 
quantified parameters are shown in Figure 33D. Signals from an array of pixels spanning the 
whole field of view are presented in the Figure 34 to demonstrate the uniform quality of 
recordings. Details of the dual imaging system are described in Appendix B.  
 
Figure 33. Left ventricular wedge preparation and optical recordings of action potentials (AP) and calcium 
transients (CaT). (A) An explanted nonfailing human heart. The region indicated by white rectangle was 
dissected and cannulated for wedge preparation. (B) The left ventricular wedge preparation from the same 
heart. (C) Pseudo-ECG (p-ECG) and representative optical recordings of AP and CaT from locations 
within sub-endocardium (sub-ENDO), midmyocardium (MID), and sub-epicardium (sub-EPI), which are 
indicated by the black stars shown in the panel B. (D) Terminology. Left: superimposed AP and CaT with 
illustrations of AP duration at 80% repolarization (APD80), CaT duration at 30% and 80% recovery 
(CaTD30 and CaTD80). Right: Close-up view of upstrokes (thin lines), and the derivatives (thick lines, 
labeled as dF/dt) with illustrations of AP-CaT delay and 10%-90% rise time of CaT. 
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Figure 34. Representative simultaneous optical recordings of action potential (AP, blue) and calcium 
transient (CaT, red). Signals are taken from the evenly spaced local regions (labeled by the brown squares) 
which span the entire mapping field of view of a left ventricular wedge preparation. The endocardium 
(ENDO) and epicardium (EPI) are labeled by the white lines. 
 
    The LV wedge preparations were paced at the ENDO at twice the diastolic pacing 
threshold. Dynamic restitution protocol was conducted in which pacing was started at a 
basic cycle length (BCL) of 1500 ms and it was gradually decreased until the ventricular 
functional refractory period was reached. Two Ag/AgCl electrodes were placed near the 
ENDO and EPI surfaces respectively to measure the pseudo-ECG. For more details of the 
Methods (tissue preparation, optical mapping system, and Western blot).  
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7.3.2 Western Blot 
Immediately after the delivery of the heart to our research lab, tissue samples at sub-
endocardium (sub-ENDO, 2 mm to the endocardium) and sub-epicardium (sub-EPI, 2 mm 
to the epicardium) were dissected from LV, frozen in liquid nitrogen, and stored at -80°C 
until use. Standard Western blot procedures were used. We used the anti-SERCA2a 
monoclonal antibody and an anti-phospholamban monoclonal antibody (Affinity 
BioReagent, Golden, CO) as well as anti-GAPDH monoclonal antibody (Sigma, St. Louis, 
MO). Chemiluminescence was measured by luminescent image analyzer LAS-4000 (Fujifilm, 
Tokyo, Japan). Protein bands were quantified by software Multi-Gauge 3.0 (Fujifilm, Tokyo, 
Japan). Protein expression was analyzed in three groups of hearts (Table 2): nonfailing hearts 
(n=6), and failing hearts due to different etiologies: nonischemic/idiopathic cardiomyopathy 
(n=6) and ischemic cardiomyopathy (n=6).  
7.3.3 Data Analysis 
All signals were low-pass filtered at 60Hz. The voltage-calcium delay was defined as the 
delay between the upstrokes of AP and CaT (Figure 33D). Each upstroke was defined at 
(dF/dt)max, where F is the voltage or calcium fluorescent signal (42). AP duration (APD) was 
measured as the time from the upstroke to 80% repolarization (i.e., APD80, Figure 33D). 
Similarly, the CaT duration (CaTD) was measured as the time from the upstroke to 30% and 
80% recovery (i.e., CaTD30 and CaTD80, Figure 33D). The 10-90% rise time of CaT was 
measured as the time from 10% CaT (close to the baseline) to 90% CaT (close to the peak, 
Figure 33D). Relaxation of CaT was quantified by the time constant (τ) of a single 
exponential fit of the CaT tail, i.e., the time from the minimum of d(CaT)/dt to the resting 
level of CaT. Sub-EPI was defined as the region within 2mm from the epicardial surface (See 
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Figure 2B on the right); midmyocardium (MID) was the 2mm-wide midmyocardial layer; and 
sub-ENDO was the region within 2mm from the endocardial surface. 
7.3.4 Statistical Analysis 
For statistical analysis, we used ANOVA. Specifically, we fit a linear mixed effects repeated 
measures model, where the patient was a random effect and other factors (failing/nonfailing, 
tissue layers, and basic cycle lengths [BCL]) were fixed effects. Models contained parameters 
that allow heterogeneous variance among levels of the failing/nonfailing by tissue-layer 
interaction and repeated measures correlation among tissue layers. We compared models by 
the small-sample-size−corrected version of Akaike information criterion. Contrasts were 
used to test the significance of differences between the failing and nonfailing groups within 
different tissue layers (sub-ENDO/MID/sub-EPI). Bonferroni adjustment was used to 
account for multiple comparisons. Detailed specifications of statistical analysis for individual 
figure are provided in the Online Data Supplement. P value less than 0.05 was considered 
statistically significant. Values were given as means ± S.D.  
7.4 Results 
7.4.1 Voltage-Calcium Delay (AP-CaT Delay) 
To quantify the EC coupling, the delay between the AP upstroke and CaT rise was measured. 
As expected, the upstroke of the AP was always followed by the rise of CaT (Figure 33D). 
To quantify the transmural heterogeneity, this delay was measured and averaged at all three 
tissue layers (sub-ENDO, MID, and sub-EPI). Figure 35A&B is a representative example 
displaying AP and CaT activation maps as well as the voltage-calcium delay. This delay is 
summarized in Figure 35C for the BCL of 1500 ms. We observed a transmural gradient of 
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this delay within the failing group. That is, the delay was significantly larger at sub-ENDO 
than sub-EPI (P = 0.015, see Figure 35B as an example). 
 
7.4.2 APD and CaTD 
We quantified APD, CaTD, and the difference between the two (i.e., CaTD - APD). Figure 
3 shows one example from a nonfailing heart (Figure 36A) and one from a failing (Figure 
36B) heart. Maps of APD80 and CaTD80 are shown for both hearts. It should be noted that 
Figure 35. Voltage-calcium (AP-CaT) 
delay. (A) Activation maps for AP 
and CaT from a failing human heart 
(#10). (B) Map for AP-CaT delay 
and the anatomic definition of sub-
ENDO, MID and sub-EPI from the 
same heart. (C) Summarized results for 
AP-CaT delay at the sub-ENDO, 
MID, and sub-EPI at a basic cycle 
length (BCL) of 1500ms in failing (F, 
n=5) and nonfailing (NF, n=6) 
hearts. 
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the color scales for APD and CaTD maps are different. It can be seen that APD80 mildly 
increased in this failing heart compared with that in the nonfailing heart, while CaTD80 was 
increased in a more substantial manner. Because of the disproportionate prolongation of  
 
Figure 36. Representative maps of APD80 and CaTD80 at the basic cycle length (BCL) of 1500ms. (A) 
APD and CaTD maps from a nonfailing human heart. (B) APD and CaTD maps from a failing human 
heart. ENDO indicates endocardium, EPI, epicardium. 
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Figure 37. APD, CaTD and the duration difference (APD-CaTD). (A) APD80, CaTD80 and the 
duration difference at the basic cycle length (BCL) of 1500ms in failing (F, n=5) and nonfailing (NF, n=6) 
hearts at sub-ENDO, MID, and sub-EPI. (B) Dynamics of APD80, CaTD80 and the duration 
difference at various cycle lengths at sub-ENDO, MID and sub-EPI. The top row in panel B is for 
nonfailing hearts, and the bottom row in panel B is for failing hearts. (C) Transmural APD and CaTD 
gradients. The gradient is calculated as the difference between the values of sub-ENDO and sub-EPI. 
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CaTD relative to APD, (CaTD80 - APD80) in the failing heart was larger than that in the 
nonfailing heart.  
    APD80, CaTD80, and (CaTD80-APD80) for both failing and nonfailing groups are 
shown in Figure 37A for the BCL of 1500 ms and are summarized in Figure 37B for 
multiple BCLs. The transmural APD and CaTD gradient represented by the sub-ENDO and 
sub-EPI duration differences are shown in Figure 37C. Transmural APD gradients are 
present in both failing and nonfailing human hearts. Similar to our previous study (90), at 
slow heart rates, this gradient was less pronounced in the failing group compared with the 
nonfailing group (Figure 37A&C-left). CaTD80 (Figure 37A-middle) also exhibited gradients 
from the endocardium to the epicardium. Interestingly, this gradient (Figure 37C) was 
significantly smaller in the failing group compared with the nonfailing group at fast heart 
rates (e.g., 100 beats/min [bpm] or BCL=600 ms) but not at slow heart rates (e.g., 40 bpm 
or BCL=1500 ms).  
    The duration difference (CaTD80 - APD80) was significantly increased at sub-ENDO in 
the failing hearts during bradycardia (P = 0.022, Figure 37A-right). As the BCL decreased, 
the duration difference was significantly decreased within the failing group, while it remained 
unchanged in the nonfailing group (Figure 37B-right). Both APD80 and CaTD80 were 
decreased as the BCL was decreased (Figure 37B-left and middle).  
    M cell islands, which contain prolonged APDs and are surrounded by large APD 
gradients, were observed previously in nonfailing human hearts (90). In the majority of the 
hearts in this study, APD decreased gradually from ENDO to EPI without the presence of 
M cells. However, M cells were observed in one nonfailing heart, where we specifically 
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searched for them (Figure 38). As shown in the map of APD80 (Figure 38B), the M-cell area 
was in the form of an isolated island rather than a continuous layer. This region exhibited a 
delayed repolarization (Figure 38E) and was surrounded by steep local APD gradients 
(Figure 38C). As shown in Figure 38D and 38E, the M-cell island had longer CaTD 
compared with neighboring regions. Other M-cell island parameters (AP-CaT delay, CaTD-
APD, CaT rise time, CaTD30/CaTD80, and τ) were not different from neighboring mid-
myocardium regions (Figure 39). 
 
Figure 38. M cell island. (A) Activation propagation from ENDO to EPI. (B) APD map at the basic 
cycle length (BCL) of 1500 ms. An island of prolonged APD is evident in this map. (C) Map of APD 
gradient at the BCL of 1500 ms. This shows that the region of prolonged APD is surrounded by steeper 
APD gradients. (D) Map of CaTD at the BCL of 1500 ms. (E) From top to bottom: psudo-EKG (p-
ECG), action potential (AP), and calcium transient (CaT) from locations (marked by asterisks in panel B) 
at sub-ENDO, sub-EPI and M-cell island.  
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Figure 39. Quantifications of nonfailing heart #11 with an M-cell island. Here shows the maps for 
APD80, AP-CaT delay, CaTD80-APD80, rise time of CaT, CaTD30/CaTD80, and the CaT 
relaxation time constant (τ). 
 
7.4.3 Morphological Changes of CaT 
There were two morphological changes in CaT in the failing hearts compared with that in 
the nonfailing hearts. Figure 40A shows two representative examples of CaT recorded at the 
sub-ENDO of a failing (top) and a nonfailing heart (bottom). The first change was a ―two-
component‖ rising phase, including an initial fast rising phase (labeled by I in Figure 40A) 
and a subsequent second slow rising phase (labeled by II in Figure 40A). This was observed 
in 3 out of 5 failing hearts but not in any of the nonfailing hearts; and it was only present at 
sub-ENDO. The second slow component resulted in a significant increase of the rise time 
of CaT (P < 0.001) from 26 ± 3 ms (nonfailing and two failing) to 49 ± 12 ms (three failing) 
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at sub-ENDO. However, if a comparison is made between nonfailing and failing groups, 
this increase would not be statistically significant (See Figure 40B). The second 
morphological difference was a more flattened plateau of CaT within the failing group, 
which is reflected by an increased ratio of CaTD30 to CaTD80. Figure 40C shows that this 
ratio was significantly increased in failing hearts compared with nonfailing hearts at MID.  
 
Figure 40. Remodeling of CaT due to heart failure. (A) Representative traces of action potential (AP) and 
calcium transient (CaT) from a failing heart and a nonfailing heart. (B) 10-90% rise time of CaT at a 
BCL of 1500ms in failing (F, n=5) and nonfailing (NF, n=6) hearts at sub-ENDO, MID and sub-
EPI. (C) Ratio of CaTD30 and CaTD80 at a BCL of 1500ms at sub-ENDO, MID, and sub-EPI. 
 
7.4.4 Relaxation of CaT  
The time constant of CaT relaxation reflects the rate of Ca2+ reuptake from the cytoplasm by 
SERCA2a and Na+/Ca2+ exchanger. We observed a gradient of the relaxation time constant 
of CaT from ENDO to EPI in both failing and nonfailing hearts. Figure 41A&B shows 
representative examples of the time constant measurement () in a failing human heart. It is 
evident that at sub-ENDO was larger than that at sub-EPI. The difference between failing 
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and nonfailing groups was not statistically significant although there was a trend of an 
increase in within the failing group (Figure 41C).  
 
Figure 41. 
failing human heart. (B) Representative traces of CaT (solid lines) from sub-ENDO (red) and sub-EPI 
(blue) and their corresponding single exponential fittings (dashed lines). (B) Summary of time constant 
-ENDO, MID, 
sub-EPI at a BCL of 1500ms. 
 
7.4.5 Protein Expression of SERCA2a and Phospholamban 
To determine the molecular mechanism of the observed gradient of presented above, we 
quantified the protein expressions of SERCA2a and phospholamban. In Figure 42, 
representative bands and the statistical summary are shown for SERCA2a (Figure 42A) and 
phospholamban (Figure 42B). We divided our samples into three groups (See Table 2) 
including nonfailing, failing with ischemic cardiomyopathy, and failing with 
nonischemic/idiopathic cardiomyopathy. Each group was subdivided into sub-ENDO and 
sub-EPI. For SERCA2a, there was a significant difference between sub-ENDO and sub-EPI 
(p < 0.001, Figure 42A; interaction between tissue layers and patient groups was not 
significant [P = 0.295]). SERCA2a expression at sub-ENDO in the ischemic group was 
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significantly lower as compared to that in the nonischemic group (P = 0.023, Figure 42A). 
For phospholamban, we did not observe any differences between sub-ENDO and sub-EPI, 
nor among any of the three groups (Figure 42B). 
 
Figure 42. Protein expressions of SERCA2a and phospholamban. Representative examples of Western 
blots (top) and normalized protein expression (bottom) are shown for SERCA2a (A) and phospholamban 
(B). NF (n=6) represents the group of nonfailing hearts; Ischemic-F (n=6) represents the group of failing 
hearts with ischemic cardiomyopathy; Nonischemic-F (n=6) represents the group of failing hearts with 
nonischemic/idiopathic cardiomyopathy. 
 
7.5 Discussions 
In the present study, we conducted for the first time the simultaneous mapping of both 
voltage and calcium in LV wedge preparations from failing and nonfailing human hearts. We 
found that HF-induced remodeling consists of (1) increased differences of AP and CaT 
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durations at sub-ENDO during bradycardia (40 bpm), (2) decreased transmural CaTD 
gradients at fast pacing rates (100 bpm), (3) a slow component of rise and a dome-shaped 
plateau in CaT, and (4) a lowered level of SERCA2a expression at sub-ENDO in failing 
human hearts with ischemic cardiomyopathy. We also found that there existed transmural 
gradients of CaTD80, CaT relaxation time constant (τ), and protein expression of SERCA2a 
in both failing and nonfailing human hearts. 
7.5.1 Implications from CaT Morphology Changes 
There was a two-component rise of CaT at sub-ENDO in three of the failing hearts, with an 
initial fast component followed by a slow second component. This was previously observed 
in isolated myocytes from failing human and canine hearts (194, 203). Piacentino et al. 
suggested that this might result from increased Ca2+ entry during the AP plateau due to less 
calcium-mediated inactivation of L-type calcium currents and increased activity of the 
Na+/Ca2+ exchanger in the reverse mode (Ca2+ influx) (203). The same mechanism could 
also explain the apparent dome shape of CaT observed in the failing hearts.  
    The morphological changes of CaT could also result from dyssynchronous Ca2+ release 
within a cell. The delayed release of Ca2+ in defective regions might be responsible for the 
slow component of rise and subsequent dome shape of CaT observed in the failing human 
hearts. Confocal line scan recordings in whole failing rat hearts revealed that the release of 
Ca2+ at some part within a cell does not occur at the time of initial depolarization but a short 
time after the depolarization (254). It is possible that the normal Ca2+ release corresponds to 
the first fast rising phase of CaT; and delayed Ca2+ release corresponds to the second slow 
component of CaT.  
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    Interestingly, this slow secondary rise of CaT was observed only in sub-ENDO region in 
60% of failing hearts. Further studies will be required to investigate the mechanisms of this 
remodeling at both molecular and tissue structural levels. 
7.5.2 APD, CaTD, and (CaTD − APD) 
The decay of CaT was markedly prolonged in isolated cells from failing human hearts (21). 
In contrast, CaTD in failing hearts was not statistically different from nonfailing hearts in 
our study. This is likely due to differences between isolated cell and tissue preparations as 
well as differences in the pacing cycle length. O’Rourke et al. showed that CaTD was 3-fold 
longer in myocytes from failing hearts at BCL of 6 seconds, but was not significantly 
different at 1-second interval when compared with myocytes from nonfailing hearts (194). 
Another possible explanation for this discrepancy is the afterload dependence of CaT, which 
indicates that mechanical work and metabolic demand is crucial for inducing the pathological 
regulation and morphological changes of CaT (246). Since mechanical work was inhibited in 
our study by blebbistatin to eliminate motion artifacts, changes of CaT therefore might not 
be as evident.  
    (CaTD - APD) was significantly increased at the sub-ENDO at a slow heart rate (40 bpm) 
in failing hearts as compared to nonfailing hearts (Figure 4A-right). That is, CaT significantly 
outlasts AP and is elevated during phase 3 of the AP. This difference in duration was 
previously proposed to promote late phase 3 early afterdepolarization (EAD) by the strong 
recruitment of electrogenic Na+/Ca2+ exchanger currents (35, 195). Though EAD was not 
observed in this study, we speculate that this might contribute to the enhanced 
arrhythmogenesis in HF by promoting EADs under conditions such as metabolic inhibition.  
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7.5.3 Transmural CaTD Gradient  
The transmural gradient of CaTD at fast heart rates (100 bpm) was significantly smaller in 
the failing group as compared to the nonfailing group. This might have important 
physiological implications relevant to the mechanical dysfunction of failing human hearts.  
    The transmural gradient of CaTD was 72 ± 20 ms and 81 ± 16 ms at a slow rate (40 bpm) 
for failing and nonfailing groups during ENDO pacing, respectively (Figure 4C-right). The 
corresponding conduction time from the ENDO to EPI was 49 ± 13 ms and 30 ± 5 ms (40 
bpm). Therefore, the transmural gradient of the time at 80% of CaT relaxation from ENDO 
to EPI (ENDO to EPI CaTD80 difference minus conduction time) was 23 ± 15 ms and 51 
± 19 ms. The positivity of these values indicates that the sequence of relaxation of CaT was 
from EPI to ENDO for both failing and nonfailing groups at 40 bpm. This sequence is the 
same as the transmural sequence of myofiber relaxation measured in vivo in normal canine 
hearts during sinus rhythm (6).  
    At fast heart rates this sequence was maintained in nonfailing human hearts (as expected) 
but was reversed in failing human hearts. At 100 bpm in the failing group, the transmural 
gradient of CaTD was 25 ± 11 ms and conduction time increased to 57 ± 13 ms at (Figure 
4C-right). Therefore, the transmural gradient of the time at 80% of CaT relaxation was -29 ± 
15 ms, the negativity of which indicates that the sequence of CaT relaxation for the failing 
group was from ENDO to EPI.  This reversed sequence of relaxation at fast heart rates 
could be associated with poor mechanical function and might be one of the mechanisms 
underlying the higher risk for primary composite endpoint in HF patients with higher heart 
rates (25).   
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7.5.4 Heterogeneous Calcium Handling  
The protein expression of SERCA2a was significantly lower in ischemic failing hearts than 
the nonischemic failing hearts, at sub-ENDO but not at sub-EPI. This indicates that the 
protein level of SERCA2a is dependent on both the etiology of HF and the anatomic 
location of the myocardium. Previously, SERCA2a was found to be significantly down-
regulated in failing human hearts in some studies (50, 109, 173, 240), while it was not in 
other studies (57, 82, 84, 152, 183, 185, 229). According to our results, the inconsistent 
observations might be related to the anatomic inconsistency within and across studies, and 
due to the etiology dependence of down-regulation.  
    In both failing and nonfailing hearts, the protein level of SERCA2a was less abundant at 
sub-ENDO than that at sub-EPI (Figure 8A). This difference was consistent with previous 
observations in canine and human hearts (140, 211). The lower expression of SERCA2a was 
suggested to lead to the larger relaxation time constant of CaT in canine hearts (140). Our 
results suggest that this causal relationship might also exist in human hearts.   
    No significant increase of the relaxation time constant was observed in failing human 
hearts in this study. Since our failing group consisted of two hearts with ischemic 
cardiomyopathy and three hearts with nonischemic/idiopathic cardiomyopathy for the 
functional part of this study, the lack of statistical significance could be explained by 
different etiologies of HF. Indeed, the time constant in hearts with ischemic cardiomyopathy 
was longer than in hearts with nonischemic/idiopathic cardiomyopathy (i.e., sub-ENDO: 
170 ms vs. 136 ms; MID: 152 ms vs. 124 ms; sub-EPI: 137 ms vs. 114 ms). Due to limited 
samples, future studies are needed to test this hypothesis. Nevertheless, this hypothesis is 
supported by a study in isolated myocytes from human hearts with end-stage HF, which 
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showed that relaxation of CaT and contraction was significantly slower in hearts with 
ischemic cardiomyopathy than that with dilated cardiomyopathy (232). This difference might 
be explained by the significant down-regulation of SERCA2a protein expression in ischemic 
failing group but no change within the nonischemic failing group as shown in this study.  
7.5.5 M Cell Island  
We have recently reported (90) that the M cells were present in the form of spatially discrete 
and isolated islands rather than a continuous layer in 3 out of 5 nonfailing human hearts. 
Moreover, M cells were not observed in failing human hearts due to nonhomogeneous APD 
prolongation and decreased transmural APD gradient (90). In order to compare failing and 
nonfailing hearts under the same pattern of APD distribution, we did not concentrate on 
searching for M cell islands in nonfailing hearts. This explains why we only present M cells in 
one nonfailing heart (Figure 5). In this experiment, we specifically searched for M cells 
which were in the form of isolated islands rather than a continuous layer, as was previously 
described (90). The regions above and below the M cell island had continuous APD gradient 
from ENDO to EPI (similar to Figure 3). To compare failing and nonfailing hearts under 
the same pattern of APD distribution, data only in the region without M cells (e.g., upper 
part of Figure 5B) were used in the statistical analysis. 
    As shown in Figure 5D, CaTD within the M cell island was prominently longer compared 
to the neighboring region. However, CaTD within the M cell island (698±9 ms) was 
comparable to that at the sub-ENDO (711±15 ms, also see Figure 5D), while APD within 
the M cell island (649±7 ms) was longer than that at sub-ENDO (618±13 ms, also see 
Figure 5B). This difference is similar to the observation made in the canine study by 
Cordeiro et al.(45) Interestingly, other parameters related to EC coupling and calcium 
120 
 
handling (such as AP-CaT delay, CaT rise time and CaT relaxation time constant) were not 
distinctly different from the surrounding region (Supplemental Figure 2). The role of M cell 
islands in the contraction and their nature in nonfailing hearts remains unclear. 
7.6 Limitations 
This study has several limiations. First, nonfailing donor hearts are not necessarily 
representative of healthy hearts (190). However, none of the donors have a history of HF, 
and were thus the best controls available for this functional study. Second, due to technical 
limitations, only a limited transmural surface of LV with good perfusion was mapped. Due 
to the anatomical heterogeneity of the heart itself, caution should be taken to extrapolate the 
results to the whole heart. Third, due to the limited access to functional human hearts, the 
number of hearts for each group is small, and might compromise the statistical significance 
of potential differences. Because all of the failing hearts with different cardiomyopathy were 
grouped together for the functional data analysis, only changes common to different 
etiologies of cardiomyopathy could be revealed. Changes unique to individual 
cardiomyopathy could be masked. Fourth, several other important aspects of EC coupling 
were not examined in this study, such as the SR calcium content and the EC coupling gain. 
Regional differences of these parameters need to be resolved in future studies. Fifth, 
application of blebbistatin in our study liberated ATP from mechanical contraction and thus 
allowed ample supply of ATP to electrophysiological processes. Pathological changes could 
thus be less evident in the absence of metabolic disturbance that could be unmasked by 
mechanical work.  Finally, as shown in neonatal rat myocyte cultures, the use of high-affinity 
dyes including Rhod-2 may overestimate CaTD, which was about twice as large as APD (71, 
72). This was not likely the case in our measurements because CaTD in normal human 
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hearts was comparable to APD. Also, the main focus of the present study was on regional 
differences of CaTDs rather than on their absolute values. Thus, potential systematic errors, 
if they existed, were likely to be subtracted or minimized. 
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8. Summary and Future Directions 
The panoramic imaging system has demonstrated its use in studying the dynamics of 
reentrant arrhythmias (149). The limitation of the current system is its relatively low spatially 
resolution due to the use of PDA (16 by 16). Incorporation of the high spatial resolution 
CMOS cameras into this system could significantly improve the performance and extend its 
application to large hearts (e.g. dog and human heart).  
     The dual imaging system has also proved its use in mouse, rabbit and human heart tissues. 
The current limitation of this system is the relative small size of the field of view, which can 
be improved by using the tandem lens configuration as showed by Laurita et al. (142).  
    We demonstrated that healed myocardial infarction could enhance the susceptibility to 
electrical alternans. This hypothesis will be tested in the failing human heart targeting the 
regions containing scars tissue. Histology of the tissue should follow the functional study to 
determine the correlation between the heterogeneous functional remodeling and structural 
remodeling.  
    As remodeling of repolarization on the RV endocardium was observed in the failing 
human heart, the next step of this study will be examination of the molecular mechanism by 
investigating the gene and protein expression of key ionic channels in tissue isolated from 
different regions of RV. Furthermore, functional, molecular and structural remodeling at the 
RV outflow tract will be quantified. And hypothesis regarding the distinctively high 
arrhythmogenesis at the RV outflow tract should be tested.  
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    Regarding the study of EC coupling remodeling in failing human heart, we have 
established the "baseline remodeling". The next step is to first determine how the adrenergic 
stimulation would change the substrate and trigger for the ventricular arrhythmia, and then 
to simulate other conditions in vivo such as the loss of metabolic capability using metabolic 
inhibition. If optical mapping of beating heart without motion artifact could be achieved, 
electrical function and arrhythmia vulnerability should be tested before and after the 
application of EC uncoupler to determine whether the mechanical loading has an impact on 
the abnormal electrical function. It remains a question that under what conditions the DAD 
and EAD could occur in the failing human heart. Answering this question could potentially 
shed light to the prevention of arrhythmia triggers in human heart failure.  
    In summary, I think the continuing technical development and ongoing animal and 
human projects in the lab carry great promise in advancing the understanding of human 
cardiac electrophysiology and in opening the door for successful clinical translations to help 
combat the cardiovascular diseases such as heart failure.   
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Appendix A. Sketch of the Panoramic Imaging 
System 
A sketch of the panoramic imaging system is shown in Figure 43.   
 
Figure 43. An overview sketch of the panoramic imaging system. (A) The hardware. The heart is placed in a 
hexagon-shaped chamber. Three photo-diode arrays (PDAs) are placed around the chamber. (B) The 
software. The geometry of the heart is first reconstructed. Then the optical signals from three PDAs are 
registered and textured onto the reconstructed surface. Reentrant arrhythmia can thus be easily visualized on 
the realistic single geometry.    
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Appendix B. Dual Imaging System for 
Simultaneous Measurement of Action Potential 
and Calcium Transient 
The tissue is co-stained via coronary perfusion with voltage sensitive dye RH237 (30μL of 
1.25mg/ml solution in DMSO, Invitrogen, Carlsbad, CA) and calcium indicator Rhod-2 AM 
(0.4-0.6mL of 1mg/ml solution in DMSO, Invitrogen, Carlsbad, CA).   
    Two halogen lamps (Newport Oriel Instruments, Stratford, CT; SciMedia, Costa Mesa, 
CA) equipped with 520 ± 45nm bandpass filters are used for excitation. Fluorescent voltage 
and calcium signals are simultaneously collected from the same field of view. Fluorescence 
emission are separated by a dichroic mirror (635nm cutoff, Omega Optical, Brattleboro, VT), 
and filtered by a 700nm longpass filter (Thorlabs, Newton, New Jersey) for voltage signals 
and by a 590 ± 15nm bandpass filter (Omega Optical, Brattleboro, VT) for calcium signals. 
The two signals are then recorded by a dual CMOS camera system (ULTIMA-L, SciMedia, 
Costa Mesa, CA).  
    A sketch of the dual imaging system is shown in Figure 44. Representative recordings of 
this system from a rabbit heart is shown in Figure 45.   
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Figure 44. A sketch of the dual imaging system. The sample recordings are from a rabbit heart.  
 
Figure 45. Sample recordings by an array of pixels from a rabbit heart. 
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